Protocol VX14-661-109, Version 4.0 Page 5 of 81
Vertex Pharmaceuticals IncorporatedNumber of Subjects Approximately 160 subjects will be  randomized (1:1) to the VX-6 61/ivacaftor 
combination therapy arm or ivacaftor monotherapy arm. Of the ra ndomized 
subjects, approximately 15% will carry an R117H mutation on the second CFTR
allele.
Study Population Male and female subjects aged [ADDRESS_529245] 
that is clinically demonstrated to be ivacaftor responsive
Investigational Drug Active substances: VX-661 and ivacaftor 
Activities: CFTR corrector and potentiator (increased chloride ion [ClÃ­] secretion)
Strength and Route of Administration: 100-mg VX-661/150-mg ivacaftor 
fixed-dose combination (light yellow) film-coated tablet for or al administration
Active substance: ivacaftor 
Activity: CF transmembrane potentiator (increased ClÃ­secretion)
Strength and Route of Administration: 150-mg ivacaftor (light blue) 
film-coated tablet for oral administration
Active substance: not applicable
Activity: placebo
Strength and Route of Administration: 0-mg film-coated placebo tablets for 
oral administration visually matching the 100-mg VX-661/150-mg ivacaftor 
fixed-dose combination tablet and the 150-mg ivacaftor tablet.
Study Duration Excluding the Screening Period (approximately 28 days in durati on) and Ivacaftor 
Run-in Period (approximately 4 weeks in duration), subjects who  complete the 
Active Comparator Treatment Period (including those who prematu rely 
discontinue study treatment) will participate in this study for  up to 13 weeks. 
During the Active Comparator Treatment Period, study drug (VX-6 61/ivacaftor or 
ivacaftor only) will be administered up to 8 weeks. 
A Safety Follow-up Visit will occur 28 days Â± [ADDRESS_529246] that is clinically demonstrated to be ivacaftor r esponsive.
This study includes the following:
xScreening Period (Week -8 to Week -4)
xIvacaftor Run-in Period where all subjects will receive ivacaft or (Week -4 to 
Day -1)
xActive Comparator Treatment Period (Day 1 through Week 8 Â± 5 day s)
xSafety Follow-up Visit (28 days Â± 7 days after the final dose o f study drug)
Protocol VX14-661-109, Version 4.0 Page 8 of 81
Vertex Pharmaceuticals Incorporated3 SCHEDULE OF ASSESSMENTS
Table 3-1 and Table 3-2 provide the schedule  of assessments during the study from the 
Screening Period through t he Safety Follow-up Visit.
All visits are to be scheduled r elative to the Day 1 Visit (firs t dose of randomized study 
drug). For example, the Week 8 (Â± 5 days) Visit would occur afte r 8 weeks of study drug 
administration in the Active Comp arator Treatment Period has be en completed (i.e., Day 57, 
first day of Week 9).
Table 3-1 Screening Period Assessments â€“ Study VX14-661-109 
Event/AssessmentScreening Period
(Week -8 Through Week -4)
ICF and assent (when applicable) X
Demographics X
Medical history X
Ophthalmological history X
CFQ-RaX
CFTR genotypebX
Height and weightcX
Ophthalmologic examinationdX
Complete PE X
FSHeX
Serum pregnancy test (all females of childbearing potential)fX
Standard digital ECGgX
Vital signshX
Pulse oximetryhX
Spi[INVESTIGATOR_419673]-R,  must be completed pr ior to the start of any other a ssessments scheduled at that visit.
bAll subjects will be tested for CFTR genotype. The results of the confirmatory genotype sample obtai ned at the 
Screening Visit must be reviewed before enrollment. In subjects  with confirmed R117H mutation, linkage to poly-T
track polymorphisms will also be determined. Specific instructi ons will be provided in the Laboratory Manual. 
cWeight and height will be measured with shoes off.
dAn ophthalmologic examination will be conducted on subjects of all ages by [CONTACT_4674]. The ophthalmologic 
examination does not need to be repeated if there is documentat ion of an examination that met the protocol criteria and 
that was conducted within 3 months before the Screening Period or if there is documentation of bilateral lens removal 
(Section 11.7.8 ). Subjects with clinically significant cataracts, lens opacity , Y-suture, or lamellar rings will be excluded 
from the study.
eFSH will be measured for any potentially postmenopausal female with at least 12 months of continuous spontaneous 
DPHQRU[LOCATION_006]HD6HUXP)6+OHYHOVPXVWEHÂ• mIU/mL to be considered postmenopausal.
fAny female subject who does not meet the criteria for non-child bearing potential is considered to be of childbearing 
potential and must have a serum pregnancy test.
gA standard digital ECG will be performed after the subject has been supi[INVESTIGATOR_1919] [ADDRESS_529247] (seated or supi[INVESTIGATOR_050]) for 5 minutes. 
iSpi[INVESTIGATOR_14438]- or postbronchodilator ( Section 11.6.1 ). Screening spi[INVESTIGATOR_139323], as specified in Section [IP_ADDRESS] .
Protocol VX14-661-109, Version 4.0 Page 9 of 81
Vertex Pharmaceuticals IncorporatedTable 3-1 Screening Period Assessments â€“ Study VX14-661-109 
Sweat chloridejX
Urinalysis X
Hematology X 
Coagulation X
Serum chemistry X
Inclusion/exclusion criteria review X
Prior and concomitant medications X
AEs and SAEsContinuous from signing of ICF and assent (where 
applicable) through Safety Follow-up Visitk
AE: adverse event; CFTR: cystic fibrosis transmembrane conducta nce regulator; CFQ-R: Cys tic Fibrosis Questionnaire-
Revised; ECG: electrocardiogram; FSH: follicle-stimulating hormo ne; ICF: informed consent form; PE: physical 
examination; SAE: serious adverse event; 
j  A sweat chloride test must be performed at the Screening Visit if an eligible sweat chloride value is not available in the 
subjectâ€™s medical records and the Screening Visit value is need ed to establish eligibility. For subjects using sweat 
chloride values documented in their medical records to establis h eligibility, the sweat chloride test at the Screening 
Visit is optional.
kFor enrolled subjects who do not have a Safety Follow-up Visit,  AEs and SAEs will be collect ed through the earliest of 
the following: [ADDRESS_529248] dose of study drug; the E TT Visit, if that visit is [ADDRESS_529249] 
dose of study drug ( Section 8.1.5 ); or prior to the first dose of study drug in the extension st udy.
Protocol VX14-661-109, Version 4.0 Page 11 of 81
Vertex Pharmaceuticals IncorporatedTable 3-2 Ivacaftor Run-in Peri od, Active Comparator Treatment Period, ETT, and Safety Follow-up Visit Assessments â€“
Study VX14-661-109 
Event/AssessmentaIvacaftor Run-in PeriodbActive Comparator Treatment Period
ETT
VisitcSafety 
Follow-up Visit
28 days 
(Â± 7 Days)
After Last DosedWeek -4 
(Day -28
Â±2D a y s )Week -2 
(Day -14)
(Â± 2 Days) Day 1Week 2
(Day 15)
(Â± 2 Days)Week 4
(Day 29)
(Â± 5 Days)Week 8
(Day 57)
(Â± 5 Days)
Complete PEhX
Pregnancy testiXX X XXX
Standard digital ECGjXX X X X XXX
Vital signskXX X X X XXX
Pulse oximetrykXX X X X XXX
Spi[INVESTIGATOR_419674] X X X X X X
Sweat chloridemXX X X X X
Urinalysis X X X X X
Hematology X X X X X X
Coagulation X X X X X
Serum chemistry XnXXnXX X X X
Lipid paneloX X X X
hSymptom-targeted PEs will occur at any time during the study if  triggered by [CONTACT_139366].
iPregnancy tests will be performed for all female subjects RIFKLOGEHDULQJSRWHQWLDO$XULQHÈ• -hCG test will be performed at the Week -4 (before first dose o f study drug), 
Day 1, and Week [ADDRESS_529250] 5 minutes. At the Day 1 and Week 2 Visits, ECGs will be 
collected before dosing and at 1.5, 3, 4, and 6 hours after the morning dose. The ECG will be per formed before the morning dose  of study drug at Week -4, Week -2, and 
Week 4. Single ECGs will be performed at Week 8, ETT, and Safet y Follow-up Visits. ECGs collected on Week -4 and Day 1 before d osing will be performed in triplicate. 
Where repeats of the same assessment are required at a given vi sit, if study drug is not administered on the day of the visit (i.e., study drug interruption or permanent 
discontinuation of study drug), only [ADDRESS_529251] (seated or supi[INVESTIGATOR_050]) for at le ast 5 minutes.
lAt all visits, spi[INVESTIGATOR_419675] -bronchodilator and before dosing ( Section 11.6.1 ). On Days 1 and 15, subjects <[ADDRESS_529252] scheduled spi[INVESTIGATOR_419676].
m  The sweat chloride collection on dosing days should occur befor e the morning dose of the study drugs. At each time point, 2 sa mples will be collected, 1 from each arm (left 
and right). Collection of sweat chloride will not overlap with any other study assessments.
n  Blood samples will be collected  before the first dose of stud y drug.
o Subjects will require [ADDRESS_529253] e for the lipid panel is obtained. 
Protocol VX14-661-109, Version 4.0 Page 12 of 81
Vertex Pharmaceuticals IncorporatedTable 3-2 Ivacaftor Run-in Peri od, Active Comparator Treatment Period, ETT, and Safety Follow-up Visit Assessments â€“
Study VX14-661-109 
Event/AssessmentaIvacaftor Run-in PeriodbActive Comparator Treatment Period
ETT
VisitcSafety 
Follow-up Visit
28 days 
(Â± 7 Days)
After Last DosedWeek -4 
(Day -28
Â±2D a y s )Week -2 
(Day -14)
(Â± 2 Days) Day 1Week 2
(Day 15)
(Â± 2 Days)Week 4
(Day 29)
(Â± 5 Days)Week 8
(Day 57)
(Â± 5 Days)
Vitamin levels X X X X
PK samplingpXX X X
RandomizationrX
Meal(s) or snack(s) at sitesXX X X X
Ivacaftor dosingtX
Randomized treatment dosinguXX X
Study drug count X X X X XX
Concomitant medicationsvX X X X X X X X 
pPK blood samples will be collected at Week -2 (before the morni ng dose and at 2 and 6 hours after the morning dose) and Week 2 (before the morning dose and at 3 and 
8 hours after the morning dose) . If study drug is not administe red at the Week -2 Visit or Week 2 Visit (i.e., study drug inte rruption or permanent discontinuation of study 
drug), a single PK blood sample will still be collected. At the ETT and the Safety Follow-up Visits (as applicable), a PK blood  sample will also be collected.
Randomization must occur after all inclusion and exclusion crite ria are met, after the [ADDRESS_529254] dose of study drug on Day 1 of the 
Active Comparator Treatment Period. Randomization will be done through IWRS. 
sFat-containing food such as a â€œstandard CFâ€ high-fat, high-calo rie meal or snack, will be provided at the site to subjects aft er all predose assessments have been completed.
tSubjects will receive ivacaftor 150 mg q12h from the Week -4 Vis it through the evening of Day -1 (1 day prior to the Day 1 Visi t). The study drug should be administered 
every 12 hours (Â± 2 hours) within 30 minutes after starting a mea l with fat-containing food such as a â€œstandard CFâ€ high-fat, hi gh-calorie meal or snack. On days of scheduled 
visits, the morning dos e of study drug will be administered at the site after predose assessments have been completed. 
uSubjects will receive ra ndomized study treatment from randomization through the evening  of the day before the Week 8 Visit. The study drug should be a dministered every 
12 hours (Â± 2 hours) within 30 minutes after starting a meal wit h fat-containing food such as a â€œstandard CFâ€ high-fat, high-ca lorie meal or snack. On days of scheduled visits, 
the morning dose of study drug will be administered at the site  after predose assessments have been completed. 
v I nformation on concomitant medications is collected through the Safety Follow-up Visit for all subjects. For subjects who disco ntinue treatment and are followed for certain 
efficacy assessments after the ETT Visit (see  Section 8.1.5 ), information on concomitant antibiotic therapy for â€œsinopulmo nary signs/symptomsâ€ are collected through the 
Week 8 Visit, as described in  Section [IP_ADDRESS].1
Protocol VX14-661-109, Version 4.0 Page 13 of 81
Vertex Pharmaceuticals IncorporatedTable 3-2 Ivacaftor Run-in Peri od, Active Comparator Treatment Period, ETT, and Safety Follow-up Visit Assessments â€“
Study VX14-661-109 
Event/AssessmentaIvacaftor Run-in PeriodbActive Comparator Treatment Period
ETT
VisitcSafety 
Follow-up Visit
28 days 
(Â± 7 Days)
After Last DosedWeek -4 
(Day -28
Â±2D a y s )Week -2 
(Day -14)
(Â± 2 Days) Day 1Week 2
(Day 15)
(Â± 2 Days)Week 4
(Day 29)
(Â± 5 Days)Week 8
(Day 57)
(Â± 5 Days)
Concomitant treatments and proceduresXX X X X
XXX
AEs and SAEs Continuous from signing of ICF and assent (where ap plicable) through Safety Follow-up Visitw
$(DGYHUVHHYHQWÈ• -hCG: beta-human chorionic gonadotropin; CF: cystic fibrosis; C FQ-R: Cystic Fibrosis Questionnai reâ€“Revised; ECG: electrocardio gram; ETT: Early Treatment 
Termination; IWRS: interactive web response system; PE: physica l examination; PK: pharmacokinetic; ; SAE: serious adverse event;  
wFor enrolled subjects who do not have a Safety Follow-up Visit,  AEs and SAEs will be collected t hrough the earliest of the fol lowing: [ADDRESS_529255] dose of study 
drug; the ETT Visit, if that visit is [ADDRESS_529256] dose of study drug ( Section 8.1.5 ); or prior to the first dose of study drug in the extension st udy.
Protocol VX14-661-109, Version 4.[ADDRESS_529257] of Figures ............................................... ............................................................... ...... 18  
5 Introduction................................................... ............................................................... .. 19  
6 Study Objectives .............................................. .............................................................. 21 
6.1 Primary Objective ............................................. ........................................................ 21  
6.2 Secondary Objectives .......................................... ..................................................... 21  
7 Study Endpoints ............................................... .............................................................. 21 
7.1 Primary Endpoints ............................................. ....................................................... 21  
7.2 Key Secondary Endpoints ....................................... ................................................. 21  
7.3 Secondary Endpoints ........................................... ..................................................... 21  
8 Study Design .................................................. ............................................................... .. 22  
8.1 Overview of Study Design ...................................... ................................................. 22  
8.1.1  Screening ..................................................... ..................................................... 23  
[IP_ADDRESS]  Repetition of Screening Assessment(s) ......................... ............................. 24  
[IP_ADDRESS]  Rescreening ................................................... ............................................. 24  
[IP_ADDRESS]  Extension of the Scree ning Period Window ...................... ........................ 24  
8.1.2  Ivacaftor Run-in Period (4 Weeks) ............................. ...................................... 24  
8.1.3  Active Comparator Treatment Period (8 Weeks) .................. ........................... 25  
8.1.4  Safety Follow-up .............................................. ................................................ 25  
8.1.5  Early Treatment Termination ................................... ........................................ 25  
8.1.6  Independent Data Monitoring Committee ......................... ............................... 26  
8.2 Rationale for Study Design a nd Study Drug Regimens ............ ............................... 26  
8.2.1  Study Design................................................... .................................................. 26  
8.2.2  Study Drug Dose and Duration .................................. ...................................... 27  
8.2.3  Rationale for S tudy Population................................. ........................................ 27  
8.2.4  Rationale for Study Assessments ............................... ...................................... 28  
9 Study Population .............................................. .............................................................. 29 
9.1 Inclusion Criteria ............................................ .......................................................... 29  
9.2 Exclusion Criteria ............................................ ......................................................... 30  
9.3 Study Restrictions ............................................ ......................................................... 32  
9.3.1  Dietary Restrictions/Pr ohibited Medications ................... ................................. 32  
9.4 Prior and Concomitant Medications ............................. ............................................ 33  
9.5 Removal of Subjects ........................................... ...................................................... 34  
9.6 Replacement of Subjects ....................................... ................................................... 35  
10 Study Drug Administration and management ...................... ...................................... 35  
10.1  Preparation and Dispensing .................................... .................................................. 35  
10.2  Administration ................................................ .......................................................... 35  
Protocol VX14-661-109, Version 4.0 Page 15 of 81
Vertex Pharmaceuticals Incorporated10.3  Method of Assigning Subjects to Treatment Groups .............. ................................. 37  
10.4  Dose Modification for Toxicity ................................ ................................................ 37  
10.5  Study Drug Interruption ....................................... .................................................... 37  
10.6  Missed Doses .................................................. .......................................................... 37  
10.7  Packaging and Labeling ........................................ ................................................... 38  
10.8  Study Drug Supply, Storage, and Handling ...................... ....................................... 38  
10.9  Drug Accountability ........................................... ...................................................... 38  
10.10  Disposal, Return, or Ret ention of Unused Drug ................. ...................................... 39  
10.11  Compliance .................................................... ........................................................... 39  
10.12  Blinding and Unblinding ....................................... ................................................... 39  
10.12.1  Blinding ...................................................... ...................................................... 39  
10.12.2  Unblinding .................................................... .................................................... 40  
11 Assessments ................................................... ............................................................... .. 41  
11.1  Timing of Assessments ......................................... .................................................... 41  
11.1.1  Informed Consent/Assent ....................................... .......................................... [ADDRESS_529258] and Disease Characteristics ........................... .............................................. 42  
11.3  Total Blood Volume ............................................ ..................................................... 42  
11.4  Pharmacokinetics .............................................. ........................................................ 42  
11.4.1  Blood Sampling ................................................ ................................................ 42  
11.4.2  Processing and Handling of P harmacokinetic Samples ............ ....................... 43  
11.4.3  Bioanalysis.................................................... .................................................... 43  
11.6  Efficacy ...................................................... ...............................................................  44 
11.6.1  Spi[INVESTIGATOR_038] .................................................... .................................................... 44  
11.6.2  Sweat Chloride Testing ........................................ ............................................ 45  
11.6.3  Cystic Fibrosis Questionnaire-Revised ......................... ................................... 46  
11.7  Safety ........................................................ ............................................................... . 47 
11.7.1  Adverse Events ................................................ ................................................. 47  
11.7.2  Clinical Laboratory Assessments ............................... ...................................... 47  
11.7.3  Physical Examinations and Vital Signs ......................... ................................... 49  
11.7.4  Electrocardiograms ............................................ ............................................... 50  
11.7.5  Contraception and Pregnancy ................................... ........................................ 50  
[IP_ADDRESS]  Contraception ................................................. ............................................ 50  
[IP_ADDRESS]  Pregnancy ..................................................... .............................................. [ADDRESS_529259] Parameters ................................ ........................................ 54  
11.7.8  Ophthalmologic Examination .................................... ....................................... 55  
Protocol VX14-661-109, Version 4.0 Page 16 of 81
Vertex Pharmaceuticals Incorporated12 Statistical and Analytical Plans .............................. ...................................................... 56  
12.1  Sample Size and Power ......................................... ................................................... 56  
12.2  Analysis Sets ................................................. ........................................................... 57  
12.3  Statistical Analysis .......................................... ......................................................... 57  
12.3.1  General Considerations ........................................ ............................................. 57  
12.3.2  Background Characteristics .................................... .......................................... 58  
[IP_ADDRESS]  Subject Disposition ........................................... ......................................... 59  
[IP_ADDRESS]  Demographics and Baseline Characteristics ..................... ......................... 59  
[IP_ADDRESS]  Prior and Concomitant Medications.............................. ............................. 60  
[IP_ADDRESS]  Study Drug Exposure and Compliance ............................ .......................... 60  
12.3.3  Efficacy Analysis ............................................. ................................................. 61  
[IP_ADDRESS]  Analysis of Primary Variables ................................. .................................. 61  
[IP_ADDRESS]  Analysis of Key Secondary Efficacy Variables .................. ....................... 61  
[IP_ADDRESS]  Analysis of Secondary Efficacy Variables ...................... ........................... 62  
12.3.4  Safety Analysis ............................................... .................................................. 62  
[IP_ADDRESS]  Adverse Events................................................. .......................................... 62  
[IP_ADDRESS]  Clinical Laboratory Assessments ............................... ................................ 63  
[IP_ADDRESS]  Electrocardiogram ............................................. ......................................... 64  
[IP_ADDRESS]  Vital Signs ................................................... ............................................... 64  
[IP_ADDRESS]  Physical Examination .......................................... ....................................... 65  
[IP_ADDRESS]  Other Safety Analysis ......................................... ....................................... 65  
[IP_ADDRESS].1  Pulse Oximetry ................................................ .................................... 65  
[IP_ADDRESS].2  Postdose Spi[INVESTIGATOR_038] ........................................... ................................. 65  
12.3.5  Interim and IDMC Analyses ..................................... ........................................ 65  
[IP_ADDRESS]  Interim Analysis .............................................. ........................................... 65  
[IP_ADDRESS]  IDMC Analysis ................................................. ......................................... [ADDRESS_529260] rative Considerati ons ..................... 66  
13.1  Adverse Event and Serious Advers e Event Documentation, Severity  Grading, and 
Reporting ..................................................... ............................................................. 6 6 
13.1.1  Adverse Events ................................................ ................................................. 66  
[IP_ADDRESS]  Definition of an Adverse Event................................. ................................. 66  
[IP_ADDRESS]  Clinically Significant Assessments ............................ ................................ 66  
[IP_ADDRESS]  Documentation of Adverse Events................................ ............................. 66  
[IP_ADDRESS]  Adverse Event Severity ........................................ ...................................... 67  
[IP_ADDRESS]  Adverse Event Causality ........................................ .................................... 68  
[IP_ADDRESS]  Study Drug Action Taken ....................................... ................................... 68  
[IP_ADDRESS]  Adverse Event Outcome ......................................... ................................... 69  
[IP_ADDRESS]  Treatment Given................................................ ......................................... 69  
13.1.2  Serious Adverse Events ........................................ ............................................ 70  
[IP_ADDRESS]  Definition of a Serious Adverse Event.......................... ............................. 70  
[IP_ADDRESS]  Documentation of Serious Adverse Events........................ ........................ 70  
[IP_ADDRESS]  Reporting Serious Adverse Events............................... .............................. 71  
[IP_ADDRESS]  Expedited Reporting and Investigator Safety Letters ........... ..................... [ADDRESS_529261] Retention .............................................. ................................................ 72  
13.2.7  Study Termination ............................................. ............................................... 73  
13.3  Data Quality Assurance ........................................ .................................................... 73  
13.4  Monitoring .................................................... ............................................................ 73  
13.5  Electronic Data Capture ....................................... .................................................... 74  
14 References .................................................... ............................................................... .... 76  
15 Protocol Signature [CONTACT_68615] ...................................... ........................................................ 79  
15.1  Sponsor Signature [CONTACT_3490] ........................................ .................................................... 79  
15.2  Investigator Signature [CONTACT_3490] ................................... ................................................... 80  
16 Appendix A: Second CFTR Allele Mutations Included for Subjects who are 
Heterozygous for the F508del-CFTR Mutation ...................................................... .... [ADDRESS_529262] of Tables
Table 3-1  Screening Period Assessment s â€“ Study VX14-661-109 .............. ..................... 8  
Table 3-2  Ivacaftor Run-in Period, Active Co mparator Treatment Period, ET T, and 
Safety Follow-up Visit Assessm ents â€“ Study VX14-661-109 ........ ................ 10  
Table 9-1  Study Restrictions ............................................ ............................................... 33  
Table 10-1  Study Drug Administration â€“ Ivacaftor Run-in Period ............ ....................... [ADDRESS_529263] of Figures
Figure 8-1  Schematic Vie w of the Study Design ............................ ................................. 23  
Protocol VX14-661-109, Version 4.0 Page 19 of 81
Vertex Pharmaceuticals Incorporated5 INTRODUCTION
Cystic fibrosis (CF) affec ts an estimate d 70,[ADDRESS_529264]  in the gene encoding the CF 
transmembrane conductance regula tor protein (CFTR), an epi[INVESTIGATOR_419677] (ClÃ­)
channel activated by [CONTACT_419722] a denosine monophosphate-dependent p rotein kinase A that is 
responsible for aiding in the r egulation of salt and water abso rption and secretion in various 
tissues.2This function is defective in pa tients with CF due to a loss of  either cell surface 
expression and/or function. 
More than [ADDRESS_529265] the quantity of 
functional cell surface CFTR protein include defects that reduc e CFTR protein synthesis and 
defects that impede the cellular processing and delivery of CFT R proteins to the cell surface.
CFTR gene mutations ass ociated with minimal CFTR function include
xmutations associated with severe defects in ability of the CFTR  channel to open and 
close, known as defective channel gating or â€œgating mutationsâ€;  
xsevere defects in the cellular  processing of CFTR and its deliv ery to the cell surface;
xno (or minimal) CFT R synthesis; and
xsevere defects in c hannel conductance.
The most prevalent mutation i s an in-frame deletion in the CFTR  gene resulting in a loss of 
phenylalanine at position 508 in the  CFTR protein (F508del-CFTR ).10In the [LOCATION_002] 
(US), almost 87% of patien ts with CF have at least 1 copy of th e F508del-CFTR mutation 
and about 47% have 2 copi[INVESTIGATOR_014].11 In the European Union (EU), a pproximately 83% of patients 
with CF have 1 or 2 copi[INVESTIGATOR_1093] F508del-CFTR mutation, and approx imately 38.7% of 
patients with CF in the U nited Kingdom have [ADDRESS_529266] been studied.9One approach is to treat wit h a compound that will modify the 
cellular processing and traffickin g of the CFTR protein to incr ease the amount of functional 
CFTR at the cell surface. Thi s kind of compound has been termed  a CFTR corrector. Another 
approach is to treat with a com pound that increases the channel  gating activity of protein 
kinase A-activated CFTR at the  cell surface to enhance ion tran sport. This kind of compound 
has been termed a potentiator. D epending on the amount of resid ual CFTR channel activity 
in the membrane and the pathophys iology of that activity (refle cting the CFTR genotype of 
the patient and possibly other factors), both approaches may be  required to ameliorate lung 
disease in patients with CF . A modest restoration of ClÃ­ secretion through the action of a 
potentiator and/or corrector coul d prevent the hyperabsorption of water across the api[INVESTIGATOR_419678], allo wing proper maintenance of air way hydration. Adequate 
airway hydration could alleviate the cycle of mucus plugging, i nfection, and inflammation, 
which leads to irreversible struc tural changes in the lungs and , eventually, respi[INVESTIGATOR_419679].
VX-661 is a compound developed by [CONTACT_419723] (Vertex) that has 
been shown to have CFTR corrector  properties. Several lines of in vitro evidence suggest that 
VX-661 works by [CONTACT_419724] a fraction of 
the F508del-CFTR protein during its biogenesis and processing i n the endoplasmic 
reticulum, allowing it to exit the endoplasmic r eticulum and tr affic the cell surface.16 When 
added for more than 24 hours to hum an bronchial epi[INVESTIGATOR_018] (HBE ) cells isolated and cultured 
from lung explants obtained fro m donors with CF (CF-HBE cells) who are homozygous for 
the F508del-CFTR mutation, a concentrati on-dependent increase in levels of matur e 
(i.e., plasma membrane) F508del-CF TR was observed. The increase d trafficking of 
F508del-CFTR to the cell surface resulted in a significant incr ease in ClÃ­secretion.16VX-[ADDRESS_529267] the processing a nd localization of other misfol ded or normally fol ded proteins 
other than CFTR, suggesting th at the mechanism of VX-661 action  is selective for CFTR 
(CFTR corrector).17
Ivacaftor (also known as VX-770) is the first CFTR modulator to  show an improvement in 
CFTR function and clini cal benefit in patients with CF. Results  from several Phase [ADDRESS_529268] mutations 
that result in gating defects as  evidenced by [CONTACT_419725] (measured by [CONTACT_419726] s weat chloride concentration ) and corresponding 
substantial, durable improvements in lung f unction, respi[INVESTIGATOR_23908], and weight gain. 
Ivacaftor was also well tolerate d, as evidenced by [CONTACT_419727] d reasons for premature 
discontinuation and results  of safety assessments. 
Kalydeco (ivacaftor) is indicate d for the treatment of CF in pa tients as young as [ADDRESS_529269] 1 of the following mutations in the CFTR gene: G551D, G1244E, G1349D, 
G178R, G551S, S1251N, S1255P, S549N, S549R , or R117H . Please refer to the ivacaftor IB 
and local prescribing informa tion or summary of product charact eristics for your region for 
the current approved use of Kalydeco. 
Details about the VX-661 and ivaca ftor development programs can  be found in the 
Investigator's Brochures.18,[ADDRESS_529270] that is clinically 
demonstrated to be ivacaftor responsive ( Section 16 ). 
This study is designed to comp are active treatment of VX-661 (1 00 mg daily [qd]) and 
ivacaftor (150 mg every 12 hours [q12h]) combination therapy wi th ivacaftor monotherapy 
(150 mg q12h).  
The treatment regimens will be as follows:
xVX-661/ivacaftor combination therapy 
oMorning dose: 1 tablet of fixed-dose combination of VX-661 100 mg/ivacaftor 
150 mg and 1 tablet of placebo visu ally matched to ivacaftor 
oEvening dose: 1 tablet of ivacaftor 150 mg 
xIvacaftor monotherapy 
oMorning dose: 1 tablet of placebo vi sually matched to the fixed -dose combination 
tablet and 1 tablet of ivacaftor 150 mg 
oEvening dose: 1 tablet of ivacaftor 150 mg 
This study includes a Screening Period (approximately 28 days),  an Ivacaftor Run-in Period 
(approximately 4 weeks), an Active Comparator Treatment Period (up to 8 weeks), and a 
Safety Follow-up Visit (approxima tely [ADDRESS_529271] dose). Following the Ivacaftor 
Run-in Period, approximately 160 s ubjects will be randomized in  a ratio of 1:1 to receive 
either VX-661/ivacaftor combina tion therapy or ivacaftor monoth erapy for 8 weeks during 
the Active Comparator Treatme nt Period. The randomization will be stratified by [CONTACT_419728] 
6FUHHQLQJ9LVLWYHUVXVÂ• years of age), type  of mutation on the second CFTR allele 
(R117H versus other allowed mutations; Section 16 ), and percent predicted FEV 1severity 
determined at the e nd of the Ivacaftor Run- in Period (<70 versu s t70; see Figure 8-1 ). Of the 
randomized subjects, approximately 15% will carry an R117H  mutation on the second CFTR
allele ( Section 16 ). Week [ADDRESS_529272] prematurely discontinued study treatment ( Section 8.1.5 ).
Protocol VX14-661-109, Version 4.0 Page 24 of 81
Vertex Pharmaceuticals Incorporated8.1.1.1 Repetition of Screening Assessment(s)
Repetition of individual screenin g assessment(s) that did not m eet eligibility criteria is not 
permitted with the following exceptions: 
xIf there is clear evidence of a l aboratory error (e.g., hemolyz ed sample) or equipment 
malfunction, collection of a repeat  sample for the appropriate laboratory test or 
assessment may be permitted with the approval of the medical mo nitor.
xExclusionary liver function tes t (LFT) levels, which may be ret ested within 14 days of 
the original screening date.
If screening spi[INVESTIGATOR_419680] (ATS)/European Respi[INVESTIGATOR_419681] (ERS) 
guidelines,20repeat spi[INVESTIGATOR_419682].
If repeat values of the individua l assessment(s) are within the  eligibility criteria and 
completed within the screening window, then the subject is elig ible for the study.
[IP_ADDRESS] Rescreening
Subjects may only be rescreened w ith the approval of the medica l monitor. If a subject is 
rescreened, all screening asse ssments will be repeated except f or CF genotypi[INVESTIGATOR_007], 
follicle-VWLPXODWLQJKRUPRQH)6+OHYHO LIVHUXP)6+OHYHOZDVÂ• mIU/mL during prior 
screening), sweat chloride, a nd the ophthalmologic examination (if performed within the last 
3 months). If a subject is resc reened, the screening window wil l begin once the first 
rescreening assessment has been initiated.
[IP_ADDRESS] Extension of the Screening Period Window
A subject may have the Screenin g Period window extended by 2 we eks for the following 
reasons:
xUnexpected operational or logis tic delays, or to meet the eligi bility criteria
xRepetition of the Screening Peri od assessments (Section [IP_ADDRESS])
xAdditional time to conduct ophtha lmologic examinations ( Section 11.7.8 ) 
8.1.2 Ivacaftor Run-in Period (4 Weeks)
The Ivacaftor Run-in Period w ill have a total duration of 4 wee ks and is designed to establish 
a reliable on-treatment (ivacafto r monotherapy) baseline for th e Active Comparator 
Treatment Period. The first dose  of open-label ivacaftor will b e administered at the Week -[ADDRESS_529273] dose of open-labe l ivacaftor will be administer ed in the evening on Day -1 
(1 day prior to the Day 1 Visit) . With prior approval of the me dical monitor, the Ivacaftor 
Run-in Period may be extended i f the subject does not meet crit eria for entry into the Active 
Comparator Treatment Period ( Section 8.1.3 ).
Study visits during the Ivacafto r Run-in Period will occur as s hown in Table 3-[ADDRESS_529274] visit in the study.
8.1.3 Active Comparator Treatment Period (8 Weeks)
The Active Comparator Treatment  Period will last  approximately 8 weeks. Subjects will be 
randomized to 1 of 2 treatment arms (VX-661/ivacaftor or ivacaft or alone) as shown in 
Figure 8-[ADDRESS_529275] stable 
CF disease (as judged by [CONTACT_093]) and have remained on  a stable CF medication 
regimen during the run-in period. If these criteria are not met  (for example, if the subject has
an acute upper or lower respi[INVESTIGATOR_33296], pulmonary exacer bation, or changes in therapy 
[including antibiotics] for pulmonary disease within 28 days be fore the Day 1 Visit [first 
dose of study drugs in the Active Comparator Treatment Period]) , possible extension of the 
Ivacaftor Run-in Period should be di scussed with the medical mo nitor. 
Study visits during the Active Comparator Treatment Period will  occur as shown in 
Table 3-[ADDRESS_529276] ete assessments for all study  visits, as described in 
Section 8.1.5.
8.1.4 Safety Follow-up
The Safety Follow-up Visit a ssessments are listed in Table 3-2 . There will be  an outpatient 
Safety Follow-up Visit 28 days Â±  [ADDRESS_529277] dose of s tudy drug for subjects who 
complete study drug dosing and for subjects who prematurely dis continue study drug dosing. 
If the Early Treatment Termina tion (ETT) Visit occurs [ADDRESS_529278]  decides to terminate study t reatment. Subjects who 
prematurely discontinue treatme nt will also be required to comp lete the Safety Follow-up 
Visit, approximately 28 (Â± 7) days  after their last dose of stu dy drug. The assessments 
performed at the Safety Follow-up Visit are listed in  Table 3-[ADDRESS_529279] udy.
8.2.2 Study Drug Dose and Duration
The dose regimen of VX-661 chose n for continued development in Phase 3 was studied in 
Study 101 in 2 CF populations: F508del-CFTR  homozygous subjects (Group 4) and 
F508del-CFTR  heterozygous subjects who had G551D-CFTR  on the other alle le (Group 7). 
The dose regimen of VX-661 100 mg qd in combination with ivacaf tor 150 mg q12h 
provided clinically meaningful a nd statistically significant im provements in percent predicted 
FEV 1 in both populations, as well as a s ignal of CFTR modulation as  assessed by [CONTACT_139375].
The dose regimen of ivacaftor planned for this study (150 mg q1 2h) is the current approved 
dose regimen for patients with C F with gating mutations who are  aged [ADDRESS_529280] 
that is clinically demonstrate d to be ivacaftor responsive. Bas ed on the results from 
Study 101 ( Section 8.2.1 ), subjects with the F508del-CFTR  mutation on only 1 allele may 
respond to VX-661/ivacaftor combin ation therapy when the second  allele is also responsive 
to potentiator modulation. 
Patients with CF who have CFTR alleles that qualify them for  inclusion in this study may 
live in a region where ivacaftor (Kalydeco) is already approved  for patients with their 
mutations and is available for us e by [CONTACT_50246]. Because of this, it is anticipated that this 
study will enroll both subjects who have been exposed to ivacaf tor within [ADDRESS_529281] not. The intent of this s tudy is to determine if 
VX-661/ivacaftor combination thera py has additiona l benefit ove r ivacaftor monotherapy in 
this population. Subjects who have be en exposed to ivacaftor wi thin [ADDRESS_529282] an FEV 1Â•DQGÂ” 90% of predicted normal for age, sex, and 
height at the Screening Visit . Those who have not been exposed to ivacaftor within [ADDRESS_529283] an FEV 1Â•DQGÂ”RISUHGLFW HGQRUPDOIRUDJH
sex, and height at the Screening Visit.
The inclusion of subjects with C F who are 12 to 17 years of age  is justified based on severity 
of disease and allometric scalin g. The overall disease status f or the adolescent and adult 
populations to be enrolled in this study is anticipated to be s imilar based on the identical 
enrollment criteria, particularly the FEV 1and the requirement for c linical stability. Both 
VX-661 and ivacaftor are predominan tly eliminated by [CONTACT_419729] P450 
(CYP) 3A4 enzymatic pathway. The m aturity of the CYP enzymes in  adolescents is expected 
to be similar to adults.21 Therefore, the low likeliho od of differences in PK of VX-661 a nd 
ivacaftor between adolescents a nd adults further supports the i nclusion of adolescents in this 
study. The dose regimen of ivacaftor planned for this study (15 0 mg q12h) is the current 
labeled dose regimen for  patients with CF with gating mutations  who are aged [ADDRESS_529284] radiogra ph abnormalities (e.g., bronchiectasis , atelectasis, infiltrates, 
hyperinflation) 
xNasal polyps, chronic sinusitis; radiographic or computed tomog raphic abnormalities 
of the paranasal sinuses 
If it is unclear whether a subj ect meets this criterion, please  consult with the medical 
monitor prior to enrollment.  
8. Stable CF disease as judged by [CONTACT_093].9. Willing to remain on a stable CF  medication regimen from Week  -[ADDRESS_529285] day 
of dosing (Week 8) or, if applicab le, the Safety Follow-up Visi t.
10. Willing to discontinue use of ph ysician-prescribed ivacaftor  (Kalydeco) from Week -[ADDRESS_529286] day of dosing (Week 8). Beginning Week -4, subjects wi ll receive ivacaftor 
(Kalydeco) as the study drug. 
9.[ADDRESS_529287]. 
For example, a
xhistory of cirrhosis with portal hypertension and/or 
xhistory of risk factors for To rsades de Pointes (e.g., familial  long QT syndrome, 
hypokalemia, heart failure, left ventricular hypertrophy, brady cardia, myocardial 
infarction, cardiomyopathy, history of arrhythmia [ventricular and atrial fi brillation], 
obesity, acute neurologic event s [subarachnoid hemorrhage, intr acranial hemorrhage, 
cerebrovascular accident, or int racranial trauma], and autonomi c neuropathy). 
2. Any of the following abnormal laboratory values at the Screen ing Visit:
xHemoglobin <10 g/dL
xAbnormal liver function defined as any 2 or more of the followi ng:  
oÂ• Ã— upper limit of normal (ULN) aspart ate aminotransferase (AST) , 
oÂ• Ã— ULN alanine aminot ransferase (ALT), 
oÂ• Ã— ULN gamma-glutamyl transpeptidase (GGT),  
oÂ• Ã— ULN alkaline phosphatase, or  
oÂ• Ã— ULN total bilirubin
x$EQRUPDOOLYHUIXQFWLRQGHILQH GDVDQ\LQFUHDVHRIÂ• Ã— ULN AST or ALT
xAbnormal renal f unction defined as JORPHUXODUILOWUDWLRQUDWHÂ”  mL/min/1.73 m
2
(calculated by [CONTACT_419730])32,33for 
Protocol VX14-661-109, Version 4.0 Page 31 of 81
Vertex Pharmaceuticals IncorporatedVXEMHFWVÂ• years of age DQGÂ”  mL/min/1.73 m2(calculated by [CONTACT_139378]-Barratt equation)34 for subjects aged 12 to 17 years (inclusive). 
3. An acute upper or lower respi [INVESTIGATOR_4416], pulmonary exac erbation, or changes in 
therapy (including antibiotics)  for pulmonary disease within 4 weeks before Week -4 
(first dose of study drug for t he Ivacaftor Run-in Period). 
4. A 12-lead ECG demonstrating QTc >[ADDRESS_529288]'s eligibility.
5. History of solid organ or hem atological transplantation. 
6. History or evidence of catar act, lens opacity, Y-suture, or l amellar rings determined to be 
clinically significant by [CONTACT_419731]. T he ophthalmologic examination doe s not need to be 
repeated if there is documenta tion of an examination meeting pr otocol criteria that was 
conducted within 3 months before the  Screening Period or if the re is documentation of 
bilateral lens removal ( Section 11.7.8 ).
7. History of alcohol or drug abuse , as deemed by [CONTACT_1188], in the past year, 
including but not limited to canna bis, cocaine, and opi[INVESTIGATOR_858] 
8. Ongoing or prior participati on in an investigational study dr ug (including studies 
investigating lumacaftor [ VX-809] or VX-661) within 30 days of the Screening Visit. 
xA washout period of 5 terminal hal f-lives of the previous inves tigational study drug 
or 30 days, whichever is longer, mus t elapse before the Screenin g Visit. The duration 
of the elapsed time m ay be longer if required by [CONTACT_4159].  
xSubjects enrolled in open-label ex tension studies of ivacaftor are not excluded from 
enrollment.
xOngoing participation in a noninter ventional study (including o bservational studies 
and studies requiring assessmen ts without administration of stu dy drug) is permitted. 
9. Use of restricted medications  or foods within the specified w indow before the first dose 
of study drug as defined in Table 9-1 .
10. Pregnant and nursing females (fe males of childbearing potent ial must have a negative 
pregnancy test at Screening and Week -4 Visits).
11. The subject or a close relativ e of the subject is the invest igator or a subinvestigator, 
research assistant, pharmacist, stu dy coordinator, or other sta ff directly involved with the 
conduct of the study. An adult (aged 18 years or older) who is a relative of a study staff 
member may be enrolled i n the study provided that 
xthe adult lives independently of  and does not reside with the s tudy staff member. 
xthe adult participates in the stu dy at a site other than the si te at which the family 
member is employed.
Protocol VX14-661-109, Version 4.0 Page 32 of 81
Vertex Pharmaceuticals Incorporated12. Colonization with organisms a ssociated with a more rapid dec line in pulmonary status 
(e.g., Burkholderia cenocepacia ,Burkholderia dolosa , and Mycobacterium abscessus ). 
For subjects who have had a history of a positive culture in th e past, the investigator 
could be guided by [CONTACT_139380] a subje ct to be considered free of 
colonization:  
xThe subject should have had [ADDRESS_529289] 
6 months. 
9.3 Study Restrictions
9.3.1 Dietary Restrictions /Prohibited Medications
Prohibited medications and cer tain foods are not allowed in thi s study (Screening Period 
through Safety Follow-up Visit) while subjects are receiving st udy drug ( Table 9-1 ). Both 
ivacaftor and VX-[ADDRESS_529290] of study pr ohibitions and cautions for foo d and medication will be 
provided in the Study  Reference Manual. 
Protocol VX14-661-109, Version 4.0 Page 33 of 81
Vertex Pharmaceuticals IncorporatedTable 9-1 Study Restrictions
Restricted Medication/FoodStudy Period
Screening PeriodIvacaftor Run-in and Active 
Comparator Treatment Period
Certain fruits and fruit juices 
(Grapefruit, grapefruit juice, 
Seville oranges, marmalade)None allowed within [ADDRESS_529291] dose of the study drug 
(Week -4)None allowed through the Safety 
Follow-up Visit
Moderate and strong CYP3A 
inducersNone allowed within [ADDRESS_529292] dose of the study drug (Week -4)None allowed through the Safety 
Follow-up Visit
Moderate and strong CYP3A 
inhibitors (except for 
ciprofloxacin)None allowed within [ADDRESS_529293] dose of the study drug 
(Week -4)None allowed through the Safety 
Follow-up Visit
Commercially available ivacaftor 
(Kalydeco)Permitted during the Screening 
Period but none allowed after the 
first dose of the study drug (Week -4)None allowed through the Safety 
Follow-up Visit
Commercially available CFTR 
modulators other than ivacaftor 
(Kalydeco)None allowed within 30 days before 
the Screening Visit.None allowed through the Safety 
Follow-up Visit
CYP: cytochrome P450.
Note: The use of restricted medication by [CONTACT_419732] a case-by-case basis 
with the medical monitor.
9.[ADDRESS_529294]'s CF 
medications, other medications , and herbal and naturopathic rem edies administered from 
[ADDRESS_529295]'s sour ce documents. For subjects who a re screened but are not 
subsequently enrolled into the s tudy, details of prior medicati on will only be documented in 
the subjects' source documents.
xSubjects must remain on a  stable medication (and supplement) re gimen for their CF from 
[ADDRESS_529296] not initiate long-te rm treatment with new 
medication from 28 days before We ek -4 through the Safety Follo w-up Visit unless it is 
discussed and approved by [CONTACT_419733]. Guideline s for stable medication 
regimens for CF are as follows:
oSubjects who are taking daily i nhaled tobramycin or other chron ically inhaled 
antibiotics should remain on that re gimen throughout the study.  
oSubjects who are on inhaled cyclin g antibiotics should continue  on their prior 
schedule. The timing  of the first dose of  study drug should be synchronized as closely 
as possible to the first day of  inhaled cycling antibiotics in the cycle.
Protocol VX14-661-109, Version 4.[ADDRESS_529297] day of 1 of th e inhaled alternating 
antibiotics.
xSubjects may receive doses of prednisone of up to 10 mg/day (ch ronically) or prednisone 
[ADDRESS_529298](s), reque st that the subject  return for a Safety Follow-up 
Visit, if applicable ( Section 8.1.4 ), and follow up with the subject  regarding any unresolved 
AEs.
If the subject withdraws consen t, no further evaluations will b e performed and no additional 
data will be collected. Vertex  may retain and continue to use a ny data collected before such 
withdrawal of consent.  
The investigator should inquire  about the reason for withdrawal  of consent.  
Subjects must return all unused s tudy drug and return for all s cheduled visits. 
A subject will be withdrawn from study treatment for any of the  following reasons: 
xA female subject or a female pa rtner of a male subject has a co nfirmed pregnancy.
xA subjectâ€™s treatment is unb linded by [CONTACT_093].
A subject may be withdrawn from st udy treatment after a discuss ion between the investigator 
and the medical monitor for an y of the following reasons: 
xA subject develops a medical c ondition that requires prolonged concomitant therapy with 
a prohibited medication or prolonge d interruption of the study drug. 
Protocol VX14-661-109, Version 4.[ADDRESS_529299] develops a life-threat ening AE or a serious adverse e vent (SAE) that places 
him/her at immediate risk, and di scontinuation of study treatme nt deemed necessary.
xA subject is noncompliant with study requirements. 
xA subject has an increase in trans aminases (ALT or AST) accordi ng to evaluations and 
management described in Section 11.7.[ADDRESS_529300] or lens opacity.
Subjects who discontinue study tre atment early should continue to return for assessments, as 
described in Section 8.1.5 .
9.6 Replacement of Subjects
Subjects who withdraw or are w ithdrawn for nonsafety reasons du ring the study drug 
treatment periods (Ivacaftor Run- in Period and Active Comparato r Treatment Period) may be 
replaced at Vertex's discretion.
10 STUDY DRUG ADMINISTRATION AND MANAGEMENT
Study drug refers to VX-661/ivacaftor, ivacaftor, and placebo t ablets visually matching the 
VX-661/ivacaftor and ivacaftor tablets.
10.1 Preparation and Dispensing
Study drug may be dispensed only  under the supervision of the i nvestigator or an authorized 
designee and only for administration to the study subjects. 
10.2 Administration
Study drug tablets will be admin istered orally. During the Ivac aftor Run-in Period, subjects 
will receive ivacaftor 150 mg  q12h from the Week -4 Visit throu gh the evening of Day -1 
(1 day prior to the Day 1 Visit)  (Table 10-1). During the Activ e Comparator Treatment 
Period, subjects will receive rando mized study treatment from r andomization through the 
evening of the day before the  Week 8 Visit. Subjects will receiv e the same number of tablets 
each day to maintain the blind durin g the Active Comparator Tre atment Period ( Table 10-2 ). 
Table 10-1 Study Drug Administr ation â€“ Ivacaftor Run-in Period
Treatment Arm TimeDrug(s) and Dose(s) Administered
Route of Administration
ivacaftorAMIVA 150-mg tablet
oral
PMIVA 150-mg tablet
oral
AM: morning; IVA: ivacaftor; PM: evening. 
Protocol VX14-661-109, Version 4.0 Page 36 of 81
Vertex Pharmaceuticals IncorporatedTable 10-2 Study Drug A dministration - Active Comparator Treatm ent Period
Treatment Arm TimeDrug(s) and Dose(s) Administered
Route of Administration
VX-661/ivacaftor
AMVX-661 100-mg/IVA 150-mg fixed-dose tablet
IVA matching placebo tablet
oral
PMIVA 150-mg tablet
oral
ivacaftor
AMVX-661/IVA matching placebo tablet
IVA 150-mg tablet
oral
PMIVA 150-mg tablet
oral
AM: morning; IVA: ivacaftor; PM: evening.
Study drug should be administere d within 30 minutes before star ting a meal with 
fat-containing food such as a â€œst andard CFâ€ high-fat, high-calo rie meal or snack according to 
the following guidelines: 
1. Throughout the Ivacaftor Run- in Period and the Active Treatme nt Comparator Period, 
study drugs will be administere d after the start and before the  end of a meal. It is 
recommended that the duration of e ach meal associated with stud y drug intake (i.e., 
breakfast and dinner/snack, as a pplicable) should not exceed 30  minutes.
2. Study drug should be admin istered q12h (Â± 2 hours). For each subject, all doses (morning 
and evening) of study drugs will  be taken at approximately the same time each day. For 
example, the morning dose coul d be taken at 08:00 every morning  and the evening dose 
could be taken at 20:[ADDRESS_529301]'s scheduled vis it is to occur in the afternoon, the following guidelines must be 
used: 
xIf the dose in the clinic will  be within [ADDRESS_529302] 's scheduled morning 
dose, the subject should withhold the ir morning dose of study d rug and the morning 
dose will be adminis tered in the clinic.
Protocol VX14-661-109, Version 4.[ADDRESS_529303]'s scheduled 
morning dose, the subject shoul d take the morning dose at home and the evening dose 
will be administered i n the clinic. In this e vent, all assessmen ts will be collected 
relative to the evening dose.
7. For visits after the Week - [ADDRESS_529304] ed to bring all used and unused 
study drug to the site; study  drug will be dispensed at each vi sit, as appropriate.
8. At the Week [ADDRESS_529305] 
dose of study drug will be the  evening dose administered the da y before the Week 8 
Visit.
10.3 Method of Assigning Subjects to Treatment Groups
Approximately 160 subjects will be s tratified by [CONTACT_419734] (<18 versus 
Â• years of age), type of mutation on the second CFTR allele ( R117H versus other allowed 
mutations;  Section 16 ), and percent predicted FEV 1severity determine d at the end of the 
Ivacaftor Run- LQ3HULRGYHUVXVÂ•DQGW KHQUDQGRPL]HGWRUHFHLY HHLWKHUWKH
VX-661/ivacaftor combination thera py or ivacaftor monotherapy d uring the Active
Comparator Treatment Period. 
An interactive web response syst em (IWRS) will be used to assig n subjects to study 
treatment, as well as to ensure randomization of approximately 15% of subjects with an 
R117H  mutation on the second CFTR allele. Detailed ins tructions for ra ndomization will be 
provided separately.  
10.[ADDRESS_529306] should 
take his/her dose with food. If  more than [ADDRESS_529307] elapsed after his/her usual dosing time, 
the subject should skip that dose and resume his/ her normal sch edule for the following dose. 
For example,
xif the morning dose of study dr ug should have been taken at app roximately 08:00, and the 
subject remembers at 12:00 that he /she forgot to take his/her d ose, he/she should take the 
dose with food as soon as possible. 
xif the morning dose of study dr ug should have been taken at app roximately 08:00, and 
more than [ADDRESS_529308] elapsed be yond the scheduled dosing time  (i.e., the time is past 
14:00), the subject would resume dos ing with the evening dose a t approximately 20:00. 
Protocol VX14-661-109, Version 4.0 Page 38 of 81
Vertex Pharmaceuticals Incorporated10.7 Packaging and Labeling
Study drug tablets will be supplied in blister cards by [CONTACT_139383].  Study drug cards will be 
provided and replaced via the IW RS. A detailed study drug dispe nsation plan will be 
provided in the Pharmacy Manual. 
Study drug labeling will be in c ompliance with applicable local  and national regulations.
10.8 Study Drug Supply , Storage, and Handling
VX-661/ivacaftor (100 mg/150 mg) and matching placebo will be s upplied as light yellow 
film-coated tablets of similar size and appearance containing 1 00 mg VX-661/150 mg 
ivacaftor and 0 mg VX-661/0 mg ivacaftor, respectively.  
Ivacaftor (150 mg) and matching  placebo will be supplied as lig ht blue film-coated tablets of 
similar size and appearance containing [ADDRESS_529309] be stored at room temperature according to T able 10-3 and to the 
instructions provided in the Pharm acy Manual. While at the clin ical site, the investigator, or 
an authorized designee (e.g., a  licensed pharmacist), will ensu re that all investigational 
product is stored in a secured a rea, under recommended study co nditions, and in accordance 
with applicable regulatory requi rement. To ensure adequate reco rds, all study drugs will be 
accounted for as detailed in Section 10.9.
Instructions regarding the storage and handling of study drug a fter dispensation to subjects 
will be provided to sites i n the Pharmacy Manual. 
Table 10-3 Identity of Stud y Drugs, Dosage, and Storage 
Drug Name [CONTACT_139419]/Formulation/Route Dosage Storage Condition
VX-661/ivacaftor 
fixed-dose tablet100-mg/150-mg tablet; oral 100 mg/
150 mg, morning doseÂ”Âƒ&Âƒ)ZLWK
excursions to 30Â°C (86Â°F)
Ivacaftor 150-mg tablet, oral 150 mg, morning and 
evening doseÂ”Âƒ&Âƒ)ZLWK
excursions to 30Â°C (86Â°F)
VX-661/ivacaftor 
matching placebo0-mg/0-mg tablet; oral 0 mg/
0 mg, morning doseÂ”Âƒ&Âƒ)ZLWK
excursions to 30Â°C (86Â°F)
Ivacaftor, matching 
placebo0-mg tablet, oral 0 mg, morning dose Â”Âƒ&Âƒ)ZLWK
excursions to 30Â°C (86Â°F)
10.[ADDRESS_529310] from the study treatment.
10.12 Blinding and Unblinding
This is a double-blind study. 
10.12.1 Blinding
The subjects and all site personne l, including the investigator , the site monitor, and the study 
team, will be blinded with the e xception of the following: 
xAny site personnel for whom thi s information is important to en sure the safety of the 
subject in the event of a life- threatening medical emergency
xAny site personnel for whom thi s information is important to en sure the safety of the 
subject and their fetus in t he event of a pregnancy 
xVertex Global Patient Safety (G PS) and Regulatory Affairs perso nnel to satisfy SAE 
processing and reporting regulations 
xUnblinded statistician pr eparing the final (production) randomi zation list who is not part 
of the study team 
xVertex Clinical Operations IWRS management
xVertex Clinical Supply Chain
Protocol VX14-661-109, Version 4.[ADDRESS_529311] access to the 
postdose spi[INVESTIGATOR_419683]. The vendor for 
central reading of the spi[INVESTIGATOR_419684] (blinded 
treatment group with dummy values  for all the spi[INVESTIGATOR_419685]) to Vertex to be used for de velopi[INVESTIGATOR_419686]. Furthermore, subjects and their caregivers should not  be informed of their 
study-related spi[INVESTIGATOR_419687] T reatment Period regardless 
of whether the subject has premat urely discontinued treatment.
Sweat Chloride Data Blinding
Despi[INVESTIGATOR_419688], knowledge of the s weat chloride dat a has the potential to suggest 
whether a subject has been admin istered active study treatment or corresponding active 
control. Therefore, during the c onduct of the study, the Vertex  study team will not have 
access to the postdose sweat chl oride data; dummy data will be used to develop statistical 
programs. During the process of  locking the clin ical database a nd after all study visits have 
been completed, treatment-blinde d access to the sweat chloride data will be provided to a 
small group of individuals who are  not involved in the study. T his group, which will consist 
of a biostatistician, a  statistical programme r, a validation st atistical prog rammer, and a 
clinical reviewer, will review the sweat chloride data to ensur e there are no significant data 
issues and will use the blinded da ta set to refine the statisti cal programs.
10.12.[ADDRESS_529312]'s treatment by [CONTACT_419735]'s study treatment 
is necessary for clinical manag ement. In such cases, investigat ors should use their best 
judgment as to whether to unbli nd without first attempting to c ontact the medical monitor to 
discuss and agree to the need f or unblinding. If investigators deem that it is not necessary to 
unblind immediately, they will first attempt to contact [CONTACT_419736]14-661-109, Version 4.[ADDRESS_529313] information for the medi cal monitor (or appropriate bac kup) will be provided in a 
separate document.
In addition, the Vertex Medical I nformation Call Center  will a nswer calls 
[ADDRESS_529314]'s treatment assignm ent has been unblinded for a me dical emergency or urgent 
clinical situation, the Vertex medical monitor should be notifi ed within [ADDRESS_529315]'s study file. Inform ation about the t reatment assig nment obtained from the 
unblinding will be maintained in a  secure location with control led access and will not be 
shared with the sponsor (Vertex ), contract research organizatio n (CRO), or any s ite personnel 
(other than the physician trea ting the subject). In addition, th e investigator will consider 
whether the clinical event tha t prompted unblinding will be con sidered an SAE, according to 
the regulatory definitions or cr iteria for SAEs, and if so, sub mit an SAE report to Vertex GPS 
or designee, per Section 13.1.[ADDRESS_529316] be 
performed in the following orde r when more than 1 assessment is  required at a particular 
time point:
3. standard 12-lead E CG recordings  
4. vital signs and pulse oximetry5. spi[INVESTIGATOR_038]6. sweat chloride7. safety laboratory assessm ents (including blood draws) 
8. PK sampling
Protocol VX14-661-109, Version 4.0 Page 42 of 81
Vertex Pharmaceuticals IncorporatedNote: where repeats of the same assessment are required at a gi ven visit, if study drug is not 
administered on the day of the vis it (for any reason, including  study drug interruption or 
premature discontinuation of s tudy drug), only 1 set of assessm ents will be collected 
(Table 3-2 ).
11.1.1 Informed Consent/Assent
Each subject of age of consent (p er local requirements) must si gn and date a study-specific 
ICF before any study-specific  procedures can be performed. Subj ects not of age of consent 
must assent, if applicable per lo cal requirements, to participa te in the study, and the subject's 
parent or legal guardian must s ign and date a study-specific IC F before any study-specific 
procedures can be performed. The  consent forms will comply with  all applicable regulations 
governing the protection of huma n subjects. An ICF and Assent F orm, approved by [CONTACT_419737]'s institutional revi ew board (IRB) or ethics commi ttee, must be used. 
11.1.[ADDRESS_529317] and disease char acteristics include the following: demo graphics, medical history, 
height, and weight. 
Medical history will be elicited from each subject during scree ning. Based on the medical 
history, the subject will be asse ssed for any disqualifying med ical conditions as specified in 
the inclusion and exclusion criteri a. The medical history shall  include a complete review of 
systems, past medical and surgi cal histories, and any allergies .
11.[ADDRESS_529318] of study drug adm inistration will be collected 
as described in Section 10.2 . The collection date  and time that each PK blood sample is 
drawn will also be recorded.
Protocol VX14-661-109, Version 4.0 Page 43 of 81
Vertex Pharmaceuticals IncorporatedDetails on sample collection, pro cessing, and shippi[INVESTIGATOR_22016] a separate 
protocol-specific Laboratory Manual.
Table 11-1 Acceptable PK Sampling Windows
Sampling Time Time From Sampling Schedule Allowed
Predose Within 60 minutes before study drug dose on PK sampling days
2, 3, 6, and 8 hours after study drug 
dosingÂ± 30 minutes
PK: pharmacokinetic.
11.4.[ADDRESS_529319] operating pro cedures. A description of the as say methods and validation 
data will be provided in separate reports. 
If appropriate, these samples m ay also be used for evaluations of metabolites of VX-661 and 
ivacaftor during treatment. These  samples may also be used for further evaluation of the 
bioanalytical method and for ana lyses that provide information on the metabolic pathways 
used or impacted by [CONTACT_94273]-661 and iv acaftor. These data will be us ed for exploratory purposes 
and may not be included in the  clinical study report. 
Protocol VX14-661-109, Version 4.0 Page 44 of 81
Vertex Pharmaceuticals Incorporated11.6 Efficacy
11.6.1 Spi[INVESTIGATOR_419689]/ERS guideline s20at the time points 
noted in Table 3-[ADDRESS_529320] 
xwithheld their short- acting bronchodilators (e.g., albuterol) o r anticholinergic 
(e.g., ipratropi[INVESTIGATOR_1893] [AtroventÂ®]) for more than 4 hours be fore the spi[INVESTIGATOR_1892];
xwithheld their long-acting bron chodilator (e.g., s almeterol) fo r more than 12 hours before 
the spi[INVESTIGATOR_1891]; and
xwithheld their once-daily, long -acting bronchodilator (e.g., ti otropi[INVESTIGATOR_1893] 
[Spi[INVESTIGATOR_35444]Â®]) for more than 24 hours before  the spi[INVESTIGATOR_1891].
During the treatment periods ( both Ivacaftor Run-in Period and the Active Comparator 
Treatment Period), spi[INVESTIGATOR_038] a ssessments must be performed bef ore dosing. In adolescent 
subjects (<18 years of age at th e Screening Visit) additional p ostdose spi[INVESTIGATOR_419690] 1 and Day 15 will be perform ed at 2 and 4 hours after th e morning dose as a safety 
assessment. A window for Â± 15 minutes will be allowed around th e nominal times for all 
postdose spi[INVESTIGATOR_31757].
During the Screening Period, spi [INVESTIGATOR_419691]- or 
postbronchodilators. At all other  visits, all spi[INVESTIGATOR_419692] 
â€œprebronchodilator.â€ 
In the event that a subject  does not withhold his/her bronchodi lator(s), spi[INVESTIGATOR_419693]: 
During the Ivacaftor Run-in Period 
xIf a subject's Week -[ADDRESS_529321] does  not withhold his/her dose of b ronchodilator, spi[INVESTIGATOR_419694], and subsequent spi[INVESTIGATOR_419695]-in Per iod (according to the schedule o f assessment s detailed in 
Table 3-2 ) should be performed postbronchodilator. 
During the Active Compar ator Treatment Period
xIf a subject's Day [ADDRESS_529322] does not  withhold his/her dose of bro nchodilator, spi[INVESTIGATOR_419696] r, and all subsequent spir ometric measurements 
during the Active Comparator Treatment Period (according to the  schedule of 
assessments detailed in Table 3-2 ) should be performed postbronchodilator. 
xSpi[INVESTIGATOR_419697] o ccur after dosing (postdose) on Da y 1 and Day 15 (for 
subjects <18 years of age at th e Screening Visit) should be per formed prebronchodilator. 
If Day 1 and/or Day [ADDRESS_529323] 
should withhold any further bronc hodilator use until after comp letion of the 4-hour 
postdose spi[INVESTIGATOR_139345]. 
xFor both Ivacaftor Run-in Peri od and the Active Comparator Trea tment Period, each 
spi[INVESTIGATOR_419698] r ecorded in the source documents as pre- or 
postbronchodilator. 
All sites will be pr ovided with spi[INVESTIGATOR_419699]. Spi[INVESTIGATOR_139347] a centralized spi[INVESTIGATOR_419700] r quality review.
Subjects and their parent/car egiver should not be informed of t heir study-related spi[INVESTIGATOR_419701] (Day 1 th rough Week 8), regardless 
of whether the subject prematur ely discontinues treatment.
The parameters listed below w ill be normalized using the standa rds of Wang et al30(for 
female subjects aged 12 to 15 years [inclusive] and male subjec ts aged 12 to 17 years 
[inclusive]) or Hankinson et al29(for female subjects aged 16 years and older and male 
subjects aged 18 years and older).  
xFEV 1(L)
xForced vital capacity (FVC) (L)
xFEV 1/FVC (ratio)
xForced expi[INVESTIGATOR_10229] (L/s) 
11.6.[ADDRESS_529324] results will 
not be disclosed to the study sites . Specific instructions for collection, handling, processing, 
and shippi[INVESTIGATOR_419702] y will be provided separately.
The sweat chloride collection on dosing days should occur befor e the morning dose of the 
study drugs. At each time point , 2 samples will be collected, 1  from each arm (left and right). 
Additionally, sweat chloride collection will be  performed at th e Screening Visit and the ETT 
Visit. For subjects using sweat c hloride values documented in t heir medical records to 
establish eligibility, the sweat chloride test at the Screening  Visit is optional. Collection of 
sweat chloride will not overlap w ith any other study assessment s.
Protocol VX14-661-109, Version 4.0 Page 46 of 81
Vertex Pharmaceuticals Incorporated11.6.3 Cystic Fibrosis Questionnaire-Revised
Subjects will be asked to complet e the CFQ-R in their native la nguage.26,35The CFQ-R will
be completed before the start of  any other assessments, as note d inTable 3-1 andTable 3-2 .
At all visits, subjects who are 12 and 13 years of age at Week - 4 will complete the CFQ-R
Child version themselves, and the ir parents/caregivers will com plete the CFQ-R Parent 
version, regardless of whether t he subject subsequently turns [ADDRESS_529325] ete the Adolescent/Adult 
version of the questionnaire them selves at all visits. The ques tionnaires provide information 
about demographics; general qua lity of life, school, work, or d aily activities; and symptom 
difficulties (pertaining to CF). Copi[INVESTIGATOR_155406]-R used in th is study will be provided in the 
Study Reference Manual.  Validated translations27,28of the CFQ-R will  be provided for 
participating centers in non-English-speaking countries.
Protocol VX14-661-109, Version 4.[ADDRESS_529326] results that are abnormal and considered clin ically 
significant will be reported as AEs ( Section 13.1.1 ). 
The safety laboratory test  panels are shown in Table 11-2.
Table 11-[ADDRESS_529327] bilirubin
Alkaline phosphataseAspartate aminotransferase Alanine aminotransferaseLactate dehydrogenaseGamma-glutamyl transpeptidase
Total protein
AlbuminCreatine kinaseAmylase
LipaseHemoglobin
Erythrocytes
Mean corpuscular hemoglobinMean corpuscular hemoglobin concentration 
Mean corpuscular volume
ReticulocytesPlatelets
LeukocytesDifferential (absolute and percent):
EosinophilsBasophils
Neutrophils
Lymphocytes Monocytes
Coagulation Studies
Activated partial thromboplastin time 
Prothrombin timeProthrombin time International 
Normalized RatioLeukocyte esterase
NitriteUrobilinogen Urine protein 
pH
Urine bloodSpecific gravity Urine ketones Urine bilirubin Urine glucose 
Vitamin Levels
Vitamin levels A, D, E, K, B12
Lipid Panel
Total cholesterol, triglyceridesLow-density lipoprotein
High-density lipoprotein
aIf urine is positive for leukocyte esterase, nitrite, protein, or blood, microscopic examination of urine will 
be performed for leukocytes, ery throcytes, crystals, bacteria, and casts.
3UHJQDQF\È• -human chorionic gonadotropin) T ests for Females of Childbearin g Potential: 
Serum samples will be obt ained as specified in Table 3-[ADDRESS_529328] 
dose of study drug.  
Protocol VX14-661-109, Version 4.0 Page 49 of 81
Vertex Pharmaceuticals IncorporatedFollicle-stimulating Ho rmone (Screening Period only): Blood sam ple for FSH will be 
measured for any potentially pos tmenopausal female with at leas t 12 months of continuous 
spontaneous amenorrhea. 6HUXP)6+OHYHOVPXVWEHÂ• 40 mIU/mL to be considered 
postmenopausal. 
CFTR Genotype (Screening Period only): CF genotypi[INVESTIGATOR_419703] d in the subject's medical record . The results of the 
confirmatory genotype sample obt ained at the Screening Visit mu st be reviewed before 
enrollment. In patient s with confirmed R117H  mutation, linkage to poly-T track 
polymorphisms will also be determin ed. Specific instructions wi ll be provided in the 
Laboratory Manual.
Additional Evaluations: Additiona l clinical laboratory evaluati ons will be performed at other 
times if judged to be clin ically appropriate. 
For purposes of study conduct, onl y laboratory tests done in th e central laboratory may be 
used. At the discretion of the lo cal investigator, local labora tories may be used for 
management of urgent medical issu es. If a local laboratory test  value is found to be abnormal 
and clinically significant, it should be verified by [CONTACT_64295] l laboratory as soon as possible 
after the investigator becomes aware of the abnormal result. If  it is not possible to send a 
timely specimen to the central laboratory (e.g., the subject was  hospi[INVESTIGATOR_419704]), the 
investigator may base the asse ssment of an AE on the local labo ratory value. 
11.7.3 Physical Examinations and Vital Signs
A PE of all body systems and vita l signs assessment will be per formed at the Screening and 
Week -4 Visits (see Table 3-1 andTable 3-2 ). At other visits, symptom-directed PEs and 
symptom-directed vital sign asse ssments can be performed at the  discretion of the 
investigator or healthcare provider .
A PE includes a review of the following systems: head/neck/thyr oid; eyes/ears/nose/throat; 
respi[INVESTIGATOR_696]; cardiovascular; lymph nodes; abdomen; skin; muscul oskeletal; and ne urological. 
Breast, anorectal, and genital examinations will be performed w hen medically indicated. 
After screening, any clinically significant abnormal findings i n PEs will be re ported as AEs.
Vital signs include blood pressu re (systolic and diastolic), te mperature (oral), pulse rate, and 
respi[INVESTIGATOR_1487]. The se will be assessed fo llowing a 5-minute r est in the seated or supi[INVESTIGATOR_12251]. 
Protocol VX14-661-109, Version 4.[ADDRESS_529329] 12-lead ECGs will be performed using a machine with pr intout according to the 
Schedule of Assessments ( Table 3-1 andTable 3-2 ). A window of Â± [ADDRESS_529330] 
12-lead ECGs will be performed at any other time if clinically indicated. The performance of 
all ECGs will adhere to the following guidelines:
xThe subject will be instructed t o rest in the supi[INVESTIGATOR_2547] f or at least [ADDRESS_529331] s, a qualified individual at the  study site will make 
comparisons to baseline measuremen ts. If the QTcF is increased by >45 msec from the 
EDVHOLQHRUDQDEVROX WH47F)YDOXHLVÂ• msec for any scheduled ECG, 2 additional ECGs 
will be performed approximately  2 to 4 minutes apart to confirm  the original measurement. If 
either of the QTcF values from th ese repeated ECGs remains abov e the threshold value 
(>45PVHFIURPEDVHOLQHRUÂ• msec), a single ECG will be r epeated at least hourly until 
QTcF values from 2 successive EC Gs fall below the threshold valu e that triggered the repeat 
measurement. 
If the QTcF value remains above  the threshold value (>45 msec f rom the average of the 
3SUHGRVHYDOXHVRQ'D\RUÂ•P VHFRQUHSHDWHGPHDVXUHPHQWR ULVQRWHGRQ
>2 occasions with no iden tified alternative e tiology for the in creased QTcF study drug, then 
discontinuation from study trea tment may be required after disc ussion with the medical 
monitor. 
Subjects who discontinue treatme nt for increased QTc should hav e their QTc monitored 
closely until it normalizes  or returns to baseline.
11.7.5 Contraception and Pregnancy
[IP_ADDRESS] Contraception
The effects of VX-[ADDRESS_529332] battery of in vitro (Ames  test, Chinese hamster ovary 
cell chromosomal aberration) a nd in vivo (mouse micronucleus) s tudies. VX-[ADDRESS_529333] and his/her partner to use at least 
[ADDRESS_529334] dose of study 
drug (unless otherwise noted) , and until [ADDRESS_529335] dose of study drug. 
Contraception for the couple is waived for the following:
xTrue abstinence for the subject, w hen this is in line with the preferred and usual lifestyle 
of the subject. Periodic abstin ence (e.g., calendar, ovulation,  symptothermal, and 
postovulation methods) and withdraw al are not acceptable method s of contraception. 
xIf the male is infertile (e.g., b ilateral orchiectomy). Inferti lity may be documented 
through examination of a semen s pecimen or by [CONTACT_419738]. 
xIf the female is of non-childbearing potential, per the followi ng: 
oPostmenopausal: spontaneous ame norrhea for at least 12 consecut ive months and 
serum FSH level Â•mIU/mL at Screening
oDocumented hysterectomy or a b ilateral oophorectomy/salpi[INVESTIGATOR_8936]-oo phorectomy 
oHas not achieved menarche (has  not had her first menstrual peri od). Females who fall 
into this category are consid ered not to be of childbearing pot ential only as long as 
they have not had their first men strual period. If a female ach ieves menarche during 
the study, she will need to provide consent for compliance (pro per method of 
contraception or abstinence).  
xNOTE: All other female subjects w ho have had their  first menstr ual period will be 
considered to be of childbearing potential. 
Acceptable contraceptive methods:
Acceptable contraceptive methods for male subjects or male partners of female subjects 
include the following: 
xVasectomy 6 months or more prev iously, with a documented negati ve postvasectomy 
semen analysis for sperm
xCondom and spermicide  
oIn countries where spermicide is not available , condom without spermicide will be 
considered acceptable.
oLocal regulations may require use of an additional acceptable m ethod of 
contraception.  
Protocol VX14-661-109, Version 4.0 Page 52 of 81
Vertex Pharmaceuticals IncorporatedAcceptable contraceptive methods for female subjects  include the following: 
xBilateral tubal ligation performe d at least 6 months previously 
xContinuous use of an intrauterine  device (non-hormone-releasing ) for at least [ADDRESS_529336] dose of study drug 
xBarrier contraception (such as  diaphragm, cervical cap, or fema le condom) and 
spermicide 
oIn countries where spermicide is  not available, ba rrier contrac eption without 
spermicide will be considered acceptable.
oLocal regulations may require us e of an additional acceptable m ethod of 
contraception.  
xNOTE: Hormonal contraceptives w ill not be consider ed as an effe ctive method; however, 
female subjects are not require d to discontinue hormonal contra ceptives. 
Acceptable contraceptive methods for female partners of male subjects: 
xBilateral tubal ligation perform ed at least [ADDRESS_529337] dose of study 
drug 
xBarrier contraception (such as  diaphragm, cervical cap, or fema le condom) and 
spermicide
oIn countries where spermicide is not available , condom without spermicide will be 
considered acceptable.  
oLocal regulations may require use of an additional acceptable m ethod of 
contraception. 
xHormonal contraceptives, if succes sfully used for at least [ADDRESS_529338] dose of 
study drug  
Additional notes:
xAcceptable methods of contracepti on listed above are examples. Local requirements may 
prohibit the use of some of these  examples. Please contact [CONTACT_315453]. 
xA female condom cannot be used w ith male condom (as a double me thod of 
contraception) due t o risk of tearing. 
xMale and female subjects who are  not sexually active at the tim e of screening must agree 
to follow the contraceptive requi rements of this study if they become sexually active with 
a partner of the opposite sex. 
xIf applicable, additional contr aception requirements may need t o be followed according 
to local regulations a nd/or requirements. 
Protocol VX14-661-109, Version 4.[ADDRESS_529339] dose of stu dy drug. 
xMale subjects whose female partne r becomes pregnant through well -documented in vitro 
fertilization (donated s perm) or banked sperm (collected before  the subject received study 
drug) must be compliant with the  contraception requirements. In  this scenario, the male 
subject and his female partner m ust commit to using barrier met hods of contraception (to 
ensure there is no exposure of t he fetus to study drug) for the  duration of the study and 
until [ADDRESS_529340] dose of study drug. 
xUnique situations that may not fa ll within the above specificat ions should be discussed 
with the medical monitor.
[IP_ADDRESS] Pregnancy
Subjects will be counseled to inf orm the investigator of any pr egnancy that occurs during 
study treatment and within [ADDRESS_529341] be permanently disc ontinued immediately. For 
male subjects, study drug does not  need to be permanently disco ntinued if the female 
partner's pregnancy resulted from donated sperm or sperm banked  before study drug 
exposure ( Section [IP_ADDRESS] ). The investigator must notify the medical monitor and Vertex 
GPS within 24 hours of the site's  knowledge of the subject's (o r partner's) pregnancy using 
the Pregnancy Information Collection Form. 
If the subject is confirmed t o be on study drug, the subject or  partner will be followed until 
the end of the pregnancy and the  infant will be followed for [ADDRESS_529342] (seated or su pi[INVESTIGATOR_050]) and before 
study drug dosing. At visits whe n study drug is taken at the si te, pulse oximetry will be 
collected before the morning dos e. This is a noninvasive measur e of oxygen delivery to the 
tissues and has been correlated w ith clinical status and lung f unction. 
Protocol VX14-661-109, Version 4.[ADDRESS_529343] Parameters
Liver Function Testing 
Liver function testing (ALT, AST, GGT, ALP, direct bilirubin, a nd total bilirubin) must be 
performed as noted in Table 3-[ADDRESS_529344] elevations of > 3 Ã— ULN and clinical 
symptoms must be followed close ly, including repeat confirmator y testing performed by [CONTACT_315452] [ADDRESS_529345] is 
>5 Ã— ULN, repeat follow-up lev els must be obtained within 7 Â± [ADDRESS_529346] ha ve the tests repeated and sent to the central laboratory as 
soon as possible (ideally within 48 to 72 hours). 
Study Drug Interruption
Study drug administration must be interrupted immediately (prior to confirmatory testing), 
and the medical monitor must be  notified, if any of the followi ng criteria is met and 
confirmed with repeat testing:
xALT or AST >8 Ã— ULN
xALT or AST >5 Ã— ULN for more than [ADDRESS_529347] >3 Ã— ULN, in assoc iation with total bilirubin >2 Ã— U LN and/or clinical 
jaundice 
A thorough investigation of pot ential causes should be conducte d, and the subject should be 
followed closely for clinical progression. 
If no convincing alternative etiology (e.g., acetaminophen use,  viral hepatitis, or alcohol 
ingestion) for the elevated tra nsaminases is identified, regard less of whether ALT or AST 
levels have improved, study trea tment must be permanently disco ntinued if repeat testing 
within [ADDRESS_529348] their trans aminases monitored closely 
until levels normalize  or return to baseline.
Resumption of Study Drug 
If an alternative, reversible cau se of transaminase elevation h as been identified, study drug 
PD\EHUHVXPHGRQFHWUDQVDPLQDV HVUHWXUQWREDVHOLQHRUDUHÂ”  Ã— ULN, whichever is higher. 
Approval of the medical monitor is required before resumption o f study drug. Upon 
resumption of study drug, trans aminases should be assessed week ly for 4 weeks. If a 
protocol-defined transaminase elevation occurs within 4 weeks o f rechallenge with the study 
drug (with confirmati on of the initial elevation by [CONTACT_419739] 48 to 72 hours), then 
the study drug must be permanent ly discontinued, regardless of the presumed etiology. 
Protocol VX14-661-109, Version 4.[ADDRESS_529349] corrected di stance visual acuity of each ey e; 
xmeasurement of lens refracting po wer following cycloplegia (e.g ., autorefractor or 
ophthalmoscopy streak); and 
xpharmacologically dilated examin ation of the lens with a slit l amp.
The screening ophthalmologic exa mination must be completed and the results reviewed 
before enrollment. This examin ation does not have to be repeate d if there is documentation 
of an examination that met protocol criteri a and that was withi n [ADDRESS_529350] is 
ineligible for study entry ( Section 9.2 ). If a cataract or lens opacity is identified and 
determined to be  clinically significant by [CONTACT_139389], the subject and 
Vertex medical monitor will be  notified. After discussion with the principal investigator, who 
collaborates with the Vertex me dical monitor, the subject may e lect to continue or 
discontinue study drug treatment . If the subject discontinues s tudy drug treatment, the subject 
should complete the ETT Visit, all subsequent scheduled visits per Table 3-2 , and the Safety 
Follow-up Visit (see Sections 8.1.4 and8.1.5 ). If the subject continues study drug treatment, 
more frequent ophthalmologic monitoring should be considered. 
In addition to the Screening Vis it, an ophthalmologic examinati on will be performed by a 
licensed ophthalmologist at the Sa fety Follow-up Visit or ETT V isit for the following 
subjects:
xsubjects <[ADDRESS_529351] 1 dose of study drug, 
xsubjects <18 years of age at the Screening Visit who complete s tudy drug treatment but 
do not enroll in a separate exte nsion study of VX-661/ivacaftor  within [ADDRESS_529352] be completed by [CONTACT_419740]-up Visit.  
SubjectsÂ•\HDUVRIDJHDWWKH6FUHHQ LQJ9LVLWDUHQRWUHTXLUHGWRFRP SOHWHRSKWKDOPRORJLF
examinations at the ETT Visit or Safety Follow-Up Visit.
Additional ophthalmologic examin ations may be conducted at the discretion of the 
investigator. The medical mon itor should be notified of any add itional ophthalmologic 
examinations.
Subjects who have documentation of b ilateral lens removal are n ot required to complete the 
ophthalmologic examination at th e Safety Follow-up Visit or ETT  Visit.
Protocol VX14-661-109, Version 4.[ADDRESS_529353] 1 dose of study drug in eith er the Ivacaftor Run-in Perio d or the Active Comparator 
Treatment Period (i.e., all subject s in the study). This analys is set will be used in subject 
listings and disposition summary tab le unless otherwise specifi ed. 
The Active Comparator Subjects Set includes all subjects random ized in the Active 
Comparator Treatment Period or  dosed with at least [ADDRESS_529354] listings related to the  Active Comparator Treatment  Period only. 
The Full Analysis Set (FAS) is  defined as all randomized subjec ts who have received at least 
[ADDRESS_529355] that is clini cally demonstrated to be 
ivacaftor responsive. 
This section presents a summary o f the planned statistical anal yses of efficacy and safety for 
this study. The Vertex Biometrics  department or a designated CR O will analyze the data 
derived from this study. Statis tical Analysis System Version 9. 2 or higher will be used to 
generate all statistical outputs (tables, figures, listings, an d data sets).
Statistical analysis and pres entation details w ill be provided in the SAP for the study. 
12.3.[ADDRESS_529356] data for  subjects exposed to study drug will be presented in data 
listings.
Continuous variables will be summarized using the following descriptive summary 
statistics: the number of subject s (n), mean, SD, median, minim um value (min), and 
maximum value (max). 
Categorical variables  will be summarized using counts and percentages.  
Baseline value, absolute change from baseline, and relative cha nge from baseline will be 
defined separately for the Ivaca ftor Run-in Peri od and the Acti ve Comparator Treatment 
Period: 
Protocol VX14-661-109, Version 4.0 Page 58 of 81
Vertex Pharmaceuticals IncorporatedxBaseline value :
oUnless otherwise specified, baselin e for the Ivacaftor Run-in P eriod will be defined as 
the most recent non-missing measur ement (scheduled or unschedul ed) collected prior 
to initial administration of Ivacaftor monotherapy. 
oUnless otherwise specified, the ba seline for the Active Compara tor Treatment Period 
will be defined as the most recen t non-missing measurement (sch eduled or 
unscheduled) collected prior t o initial administration of the V X-661/ivacaftor 
combination therapy, but no earlier than the measurement at Wee k -2. 
oFor spi[INVESTIGATOR_038], the baseline valu e used for the Active Comparat or Treatment Period 
will be the average of the measur ement at Week -[ADDRESS_529357] has an AE leading to an approved extensio n of the Ivacaftor 
Run-in Period, and the Week -2 spi[INVESTIGATOR_419705] (inclusive) of the AE, t hen the measurement on Day [ADDRESS_529358] day of the corresponding treatment pe riod. 
xChange (absolute cha nge) from baseline will be calculated as postbaseline 
value - baseline value.
xRelative change from baseline will be calculated as (postbaseline value - baseline 
value)/baseline value.
The Treatment-emergent (TE) Per iod will be defined separately f or the Ivacaftor Run-in 
Period and the Active Compar ator Treatment Period: 
xThe TE Period for the Ivacaftor Ru n-in Period is defined as the  first dose in the Ivacaftor 
Run-in Period to the earlier of t he last day prior to the first  dose of the Active Comparator 
Treatment Period or either the S afety Follow-up Visit or 28 day s (inclusive) after the last 
dose for subjects who do not have S afety Follow-up Visit in the  Ivacaftor Run-in Period.  
xThe TE Period for the Active Comp arator Treatment Period is def ined as the first dose of 
the Active Comparator Treatment  Period to the Safety Follow-up Visit or 28 days 
(inclusive) after the last dos e for subjects who do not have Sa fety Follow-up Visit in the 
Active Comparator Treatment Period. 
The TE Period will be use d for all safety analyses in the corre sponding treatment period.  
12.3.[ADDRESS_529359] Disposition
Number and percentage of subjects in the following categories w ill be summarized separately 
for the Ivacaftor Run-in Peri od and the Active Comparator Treat ment Period, as appropriate: 
xAll Subjects Sets
xDosed (Safety Set) in the  Ivacaftor Run-in Period 
xCompleted treatment in the  Ivacaftor Run-in Period
xPrematurely discontinued the tr eatment during the Ivacaftor Run -in Period and the 
reasons for treatment discontinuation 
xPrematurely discontinued the study during the Ivacaftor Run-in Period and the reasons 
for study discontinuation 
xActive Comparator Subjects Set  (Randomized or dosed) in the Act ive Comparator 
Treatment Period
xRandomized in the Active Comp arator Treatment Period 
xDosed (Safety Set) in the Activ e Comparator Treatment Period
xRandomized and dosed (FAS)  in the Active Comp arator Treatment P eriod 
xCompleted treatment i n the Active Comparat or Treatment Period
xPrematurely discontinued the tr eatment during the Active Compar ator Treatment Period 
and the reasons for tr eatment discontinuation 
xPrematurely discontinued the study during the Active Comparator  Treatment Period and 
the reasons for study discontinuation 
xCompleted study/Safety Follow-up Visit 
xPrematurely discontinued the study  after the Active Comparator Treatment Period and 
the reasons for study discontinuation 
xRollover to extension study 
[IP_ADDRESS] Demographics and Baseline Characteristics
Demographic, background (e.g., m edical history), and baseline c haracteristics will be 
summarized separately for the Iv acaftor Run-in Period and the A ctive Comparator Treatment 
Period. Protocol deviations/vio lations will be provided as a su bject data listing only.  
The following demographics a nd baseline characteristics will be  summarized: sex, race, 
ethnicity, age, weight, height, BMI, region, baseline percent p redicted FEV 1, baseline sweat 
chloride, and baseline score of C FQ-R respi[INVESTIGATOR_1798]. The s ummary will be based on the  
Safety Set for the Ivacaftor Run- in Period. For the Active Compa rator Treatment Period, the 
summary will be based on the FAS.  
Protocol VX14-661-109, Version 4.0 Page 60 of 81
Vertex Pharmaceuticals Incorporated12.3.2.3 Prior and Concomitant Medications
Medications used in this study w ill be coded by [CONTACT_419741]-Drug 
Dictionary Enhanced and categ orized as the following:  
xPrior medication: any medication that started bef ore initial dosing of study drug  in the 
Ivacaftor Run-in Period, re gardless of when it ended. 
xConcomitant medication durin g the Ivacaftor Run-in Period : medication continued 
or newly received at or after in itial dosing of the study drug through the end of the TE 
Period for the Ivacaftor Run-in Period.  
xConcomitant medication during the  Active Comparator Treatment P eriod:
medication continued or newly rec eived at or after initial dosi ng of study drug through 
the end of the TE Period of the Ac tive Comparator Treatment Per iod. 
xPost-treatment medication:  medication continued or newl y received beyond the TE 
Period of the Active Compar ator Treatment Period.
A given medication can be classi fied as a prior medication, a c oncomitant medication 
(concomitant medication during th e Ivacaftor Run-in Period and/ or a concomitant medication 
during the Active Comparator Tr eatment Period), or a post-treat ment medication; both prior 
and concomitant; both c oncomitant and post-treatment; or prior,  concomitant, and post-
treatment. If a medication has a missing or partial missing sta rt/end date or time and cannot 
be determined whether  it was taken before i nitial dosing, conco mitantly, or beyond the TE 
Period, it will be considered a s prior, concomitant, and post-t reatment.
Prior medications and c oncomitant medications in the Ivacaftor Run-in Period will be 
summarized descriptively based on t he Safety Set in that period .  
Prior medications, conc omitant medication in the Ivacaftor Run- in Period will be 
summarized descriptively again ba sed on the FAS for the Active Comparator Treatment 
Period. Concomitant medications in t he Active Comparator Treatm ent Period will also be 
summarized descriptively based on the FAS.  
Post-treatment medications will be listed for each subject.
[IP_ADDRESS] Study Drug Exposure and Compliance
Study drug exposure and complia nce will be summarized separatel y for the Ivacaftor Run-in 
Period and Active Comparator Trea tment Period. Exposure to stud y drug (i.e., duration of 
treatment) will be su mmarized for the Safety Set for the Ivacaf tor Run-in Per iod and the FAS 
for the Active Comparator Trea tment Period in terms of duration  of treatment a subject 
received (in days), defined as th e last day minus the first day  of study drug in the 
corresponding treatment period pl us 1, regardless of any interr uptions in dosing. Dosing 
compliance is calculated as the actual number of dosing occasio ns at which study drug was 
administered, as a percentage of  the planned number of dosing o ccasions, for the 
corresponding treatment period. D osing compliance will be summa rized for the Safety Set 
for the Ivacaftor Run-in Peri od and for the FAS f or the Active Comparator Treatment Period. 
Duration of treatment and dosing compliance will be summarized by [CONTACT_306028].
Protocol VX14-661-109, Version 4.0 Page 62 of 81
Vertex Pharmaceuticals IncorporatedxAbsolute change in the CFQ-R respi [INVESTIGATOR_419706] 8 in the Active Comp arator Treatment Period: Analysis of this domain will be 
similar to that of the primary analysis of the primary efficacy  endpoint, with the addition 
of the CFQ-R respi[INVESTIGATOR_1798] s core at baseline as a covariate .
Adjustment for Mul tiple Comparisons
A hierarchical testing procedur e will be used to control the Ty pe I error for the multiple 
HQGSRLQWVWHVWHGDWÄ®  = 0.05. For a test at any step to be considered statistically significant 
within the testing hierarchy, it must be statistically signific ant, and all previous tests (if any) 
within the hierarchy must be sta tistically significant, at the 0.05 level. The testing hierarchy 
is as follows: 
1. Absolute change i n percent predicted FEV 1 from baseline through Week 8 
2. Relative change in percent predicted FEV 1 from baseline through Week 8 
3. Absolute change in CFQ-R res pi[INVESTIGATOR_419707] 8 
[IP_ADDRESS] Analysis of Secondary Efficacy Variables
Absolute change in sweat chlorid e from baseline through Week 8 in the Active 
Comparator Treatment Period : Analysis of this variable w ill be performed using the same 
model as described for the absolu te change in percent predicted  FEV 1 from baseline, with the 
addition of baseline sweat chlor ide value as a covariate.
12.3.4 Safety Analysis
Safety analyses will  be based on the Safety Se t with the associ ated TE Period and separately 
for the Ivacaftor Run-in Peri od and the Active Comparator Treat ment Period, as appropriate. 
The overall safety profile of stu dy drug will be assessed in te rms of the following safety and 
tolerability endpoints: 
xIncidence of treatment-emerg ent adverse event (TEAEs)
xClinical laboratory values (i. e., urinalysis, hematology, serum  chemistry, coagulation 
studies, vitamin levels, lipid panel)
xECGs
xVital signs
xPulse oximetry
xSpi[INVESTIGATOR_419708] d in individual subject data li stings. 
[IP_ADDRESS] Adverse Events
For analysis purposes, AEs will be  classified as  pretreatment A Es, TEAEs during the 
Ivacaftor Run-in Period, TEAEs dur ing the Active Comparator Tre atment Period, or 
post-treatment AEs, de fined as follows: 
Protocol VX14-661-109, Version 4.0 Page 63 of 81
Vertex Pharmaceuticals IncorporatedxPretreatment AE:  any AE that started before ini tial dosing of study drug in the  Ivacaftor 
Run-in Period. 
xTEAEs during the Ivac aftor Run-in Period : any AE that increased in severity or that 
was newly developed at or after  initial dosing of study drug th rough the end of the TE 
Period for the Ivacaftor Run-in Period. 
xTEAEs during the Active Co mparator Treatment Period: any AE that increased in 
severity or that was newly deve loped at or after initial dosing  of study drug through the 
end of the TE Period for  the Active Comparat or Treatment Period . 
xPost-treatment AE: any AE that increased in severit y or that was newly developed 
beyond the TE Period. 
For AEs with missing or partial start dates, if there is no cle ar evidence that the AEs started 
before or after study treatment , then the AEs w ill be classifie d as TEAEs. If there is no clear 
evidence that the AEs started be fore or after the start of the Active Comparator Treatment, 
then the AEs will be c lassified as TEAEs dur ing the Active Comp arator Treatment Period.
AE summary tables will be presen ted for TEAEs, separately for t he Ivacaftor Run-in Period 
and the Active Comparator Trea tment Period, and will include th e following: 
xAll TEAEs 
xTEAEs by [CONTACT_419742] (i.e., number and percentage o f subjects with an event as 
well as total number of events) . When summarizing the number an d percentage of subjects 
with an event, subjects with mul tiple occurrences of the same A E or a continuing AE will be 
counted once, only the maximum seve rity level will be presented  in the severity summaries, 
and the worst/highest relati onship level will be presented in t he relationship summaries. An 
AE overview table will be provide d. A separate table will summa rize all TEAEs when each 
of them is considere d unique, hereafter referred to as an AE co unt table. In addition, a listing 
containing individual subject A E data for all deaths and other serious and significant AEs 
will be provided separately. All AEs, including pre- and post-t reatment AEs, will be 
presented in individual subject data listings. 
[IP_ADDRESS] Clinical Laboratory Assessments
The raw values and change from the corresponding treatment peri od baseline values of the 
continuous laboratory paramete rs will be summarized in SI units  at each scheduled time 
point during the TE Period based on t he corresponding Safety Se t for the Ivacaftor Run-in 
Protocol VX14-661-109, Version 4.[ADDRESS_529360] 1 potential ly clinically significant (PCS) 
event during the treatment-eme rgent period will be summarized f or the Ivacaftor Run-in 
Period and by [CONTACT_419743], separately. 
The PCS (postbaseline) shift from the corresponding treatment p eriod baseline will also be 
summarized for selected laborator y parameters for the Ivacaftor  Run-in Period and by 
[CONTACT_419744], sep arately, separately. The 
PCS criteria and the pa rameter selection c riteria will be provi ded in the SAP. 
Results of urinalysis and the seru m pregnancy test will be list ed in individual subject data 
listings only. In addition, a listing containing individual sub ject laboratory assessment values 
outside the reference ranges w ill be provided. This listing wil l include data from scheduled 
and unscheduled time points. 
[IP_ADDRESS] Electrocardiogram
The raw values and change from the corresponding treatment peri od baseline values will be 
summarized at each scheduled time point during the TE Period ba sed on the corresponding 
Safety Set for the Ivacaftor R un-in Period and by [CONTACT_419745]. The analyzed sta ndard digital ECG measurement s include PR, QT, and 
QTc for heart rate (HR) interv al (QTcF), QRS duration, and HR. In addition, the mean value 
of QTc at each visit w ill be plotted for the S afety Set in the Ivacaftor Run-in Period and by 
[CONTACT_419746], se parately. 
The number and percentage of subj ects with at least 1 PCS event  in the corresponding TE 
Period will be tabulated for the  Ivacaftor Run-in Period and by  [CONTACT_419747], separately. The PCS criteri a for ECG data will be 
provided in the SAP. 
Additional ECG analyses w ill be described in the SAP. 
[IP_ADDRESS] Vital Signs
The raw values and change from the corresponding treatment peri od baseline values will be 
summarized at each scheduled time point during the TE Period ba sed on the corresponding 
Safety Set in the Ivacaftor Run- in Period and by [CONTACT_39815] p in the Active Comparator 
Treatment Period: systolic a nd diastolic blood pressure (mm Hg) , body temperature ( qC), 
pulse rate (beats per minute [bpm ]), and respi[INVESTIGATOR_697] (brea ths per minute).  
The number and percentage of subj ects with at least 1 PCS event  during the TE Period based 
on the corresponding Safety Set w ill be tabulated for the Ivaca ftor Run-in Period and by 
[CONTACT_419748]. The  PCS criteria for vital signs 
data will be provi ded in the SAP. 
Additional vital sign analyses will be described in the SAP.
Protocol VX14-661-109, Version 4.0 Page 65 of 81
Vertex Pharmaceuticals Incorporated12.3.4.5 Physical Examination
PE findings will be presented as a data listing only. Clinicall y relevant results  identified after 
screening will be r eported as AEs. 
[IP_ADDRESS] Other Safety Analysis
[IP_ADDRESS].1 Pulse Oximetry
The raw values and change from the corresponding treatment peri od baseline values will be 
summarized at each scheduled time point during the TE Period ba sed on the corresponding 
Safety Set for the Ivacaftor R un-in Period and by [CONTACT_419749], separately. I n addition, the mean value at ea ch visit during the TE Period 
will be plotted for the Ivacaftor Run-in Period and by [CONTACT_22058] t group for the Active 
Comparator for the perce nt of oxygen saturation.  
[IP_ADDRESS].2 Postdose Spi[INVESTIGATOR_419709] 2-hour and 4-hour postdos e spi[INVESTIGATOR_419710] D ay 1 and Day 15, a 
summary of raw values for percent predicted FEV 1 will be provided by [CONTACT_419750]. The absolute change  from the predose value of percent predicted FEV 1 on 
the same day will be provided by [CONTACT_419751] p oint. In addition, a boxplot 
by [CONTACT_139407]. W ithin each treatment group, Da y 1 and Day 15 values will 
be presented on the same plot. 
The above analyses w ill be repeated for FEV 1.
In addition, the number and percen tage of subjects with percent  predicted FEV 1GHFOLQHÂ•
Â•DQG Â•  percentage points in the absolut e change from the predose valu e will be 
summarized by [CONTACT_1570] a nd by [CONTACT_419752]. 
12.3.5 Interim and IDMC Analyses
[IP_ADDRESS] Interim Analysis
No interim analyses of efficacy are planned.
[IP_ADDRESS] IDMC Analysis
An IDMC will be formed before s tudy initiation. The IDMCâ€™s obje ctives and operational 
details will be defined i n a separate document (IDMC charter), which will be fin alized before 
the first subject is screened. T he IDMC will conduct regular pl anned safety reviews of study 
data as outlined in the IDMC charter.
12.4 Clinical Pharmacology Analysis
A detailed description of  the clinical pharmacology analyses wi ll be provided in a CPAP. 
Listings of plasma concentra tion data of VX-661, ivacaftor, and  their metabolites will be 
provided in the clinical study r eport. A population approach wi ll be used to analyze the time-
versus-plasma concentration da ta of VX-661, ivacaftor, and thei r metabolites. The PK/PD 
relationship between concentrati ons of VX-661 and ivacaftor (an d their metabolites as 
appropriate) and efficacy and safet y measurements may be invest igated. The results of the 
PK and PK/PD analyses using a  population approach will be prese nted in a separate report. 
Protocol VX14-661-109, Version 4.0 Page 66 of 81
Vertex Pharmaceuticals Incorporated13 PROCEDURAL, ETHICAL, REGULATORY, AND ADMINISTRATIVE 
CONSIDERATIONS
13.1 Adverse Event and Serious Adverse Event Documentation, 
Severity Grading, and Reporting
13.1.1 Adverse Events13.1.1.1 Definition of an Adverse Event
An AE is defined as any untowar d medical occurrence in a subjec t during the study; the 
event does not necessarily have a causal relationship with the treatment. This includes any 
newly occurring event or worse ning of a preexisting condition ( e.g., increase in its severity or 
frequency) after the ICF is signed.  
An AE is considered serious i f it meets the definition in Section [IP_ADDRESS] .
[IP_ADDRESS] Clinically Significant Assessments
Study assessments including la boratory tests, ECGs, PEs, pulse oximetry, and vital signs, 
will be assessed and thos e deemed a clinical ly significant wors ening from baseline 
documented as an AE. When possibl e, a clinical diagnosis for th e study assessment will be 
provided, rather than the abnorma l test result alone (e.g., uri nary tract infection, anemia). In 
the absence of a diagnosis, the  abnormal study assessment itsel f will be listed as the AE (e.g., 
bacteria in urine or de creased hemoglobin). 
An abnormal study asse ssment is considered clinically significa nt if the subject has 1 or more 
of the following: 
xConcomitant signs or symptoms related to the abnormal study ass essment
xFurther diagnostic testing or med ical/surgical intervention
xA change in the dose of study drug or discontinuation from the study 
Repeat testing to determine whe ther the result is abnormal, in the absence of any of the above 
criteria, does not necessarily meet clinically significant crite ria. The determination of 
whether the study assessment results are clinically significant  will be made by [CONTACT_1275].
A laboratory value that is Grad e [ADDRESS_529361] indic ates a life-threatening AE.
[IP_ADDRESS] Documentation of Adverse Events
All AEs will be collected from the time ICF is signed until the  following time points:
xFor subjects who do not enroll: un til time of screen failure (e .g., screen failure, 
withdrawal of consent) 
xFor enrolled subjects who have a Safety Follow-up Visit: throug h the Safety Follow-up 
Visit
Protocol VX14-661-109, Version 4.[ADDRESS_529362] a Safety Follow-up Visit:  the earliest of
o28 days after the last dose of study drug
oThe ETT Visit, if that visit is [ADDRESS_529363] dose of study drug 
(Section 8.1.5 )
oprior to the first dose of stu dy drug in the extension study  
All subjects will be queried, us ing non-leading questions, abou t the occurrence of AEs at 
each study visit. When possible , a constellation of signs and/o r symptoms will be identified 
as [ADDRESS_529364]'s source documents. The following data will be 
documented for each AE: 
xDescription of the event 
xClassification of â€œseri ousâ€ or â€œnonseriousâ€ 
xDate of first occurrence and date  of resolution (if applicable)  
xSeverity
xCausal relationship to study drug(s)  
xAction taken  
xOutcome 
xConcomitant medication or  other treatment given
xIndication of dose limiting toxicity
[IP_ADDRESS] Adverse Event Severity
The investigator will determine and record the severity of all serious and non-serious AEs. 
The guidance available at the f ollowing website will be consult ed: Common Terminology 
Criteria for Adverse Events (CTCAE), Version 4.0, Cancer Therapy  Evaluation Program, 
http://ctep.cancer.gov/protocolDevelopment/electronic_applicati ons/ctc.htm (Accessed 
August 2012). AEs of CTCAE Grade s 4 and 5 will be documented as â€œlife-threatening.â€ In 
considering the severity of an A E in a pediatric subject, the i nvestigator will consider that 
reference ranges for pediatric c linical laboratory parameters m ay differ from those given in 
the CTCAE. The severity of an A E that does not appear in the CT CAE will be determined 
according to the definitions in Table 13-1 .  
Protocol VX14-661-109, Version 4.0 Page 68 of 81
Vertex Pharmaceuticals IncorporatedTable 13-1 Grading of AE Severity
Classification Definition
Mild (Grade 1) Mild level of discomfort and does not interfere with regular ac tivities
Moderate (Grade 2) Moderate level of discomfort and  significantly interferes with regular activities
Severe (Grade 3) Significant level of discomfort and prevents regular activities
Life-threatening (Grade 4) Any adverse drug experience that places the subject, in the vie w of the 
investigator, at immediate risk of death
AE: adverse event.
[IP_ADDRESS] Adverse Event Causality
Every effort will be made by [CONTACT_419753], if any, to 
the study drug(s). Causality w ill be classified using the categ ories presented in Table 13-2.
Table 13-[ADDRESS_529365] been ruled out, and/or the event re-appeared on re-ex posure to the 
investigational study drug.
Possibly related There is an association between the event and the administratio n of the 
investigational study drug and there is a plausible mechanism f or the event to be 
related to investigational study drug, but there may also be al ternative etiology, 
such as characteristics of the s ubjectâ€™s clinical status or und erlying disease.
Unlikely related The event is unlikely to be related to the investigational stud y drug and likely to 
be related to factors other than investigational study drug. 
Not related The event is related to an etiology other than the investigatio nal study drug (the 
alternative etiology will be documented in the study subject's medical record).
AE: adverse event.
[IP_ADDRESS] Study Drug Action Taken
The investigator will classify the study drug action taken with  regard to the AE. The action 
taken will be classified accordin g to the categories shown in Table 13-[ADDRESS_529366] to an AE 
Classification Definition
Dose not changed Study drug dose not changed in response to an AE.
Dose reduced Not applicable for this study
Drug interrupted Study drug administration interrupted in response to an AE.
Drug withdrawn Study drug administration permanently discontinued in response to an AE.
Not applicable Action taken regarding study drug administration does not apply . 
â€œNot applicableâ€ will be used in circumstances such as when the  investigational 
treatment had been completed before the AE began and no opportu nity to decide 
whether to continue, interrupt, or withdraw treatment is possib le.
AE: adverse event.
[IP_ADDRESS] Adverse Event Outcome
An AE will be followed until the investigator has determined an d provided the final outcome. 
The outcome will be cla ssified according to the categories show n in Table 13-4.
Table 13-4 Classification s for Outcome of an AE 
Classification Definition
Recovered/Resolved Resolution of an AE with no residual signs or symptoms
Recovered/ Resolved 
With SequelaeResolution of an AE with residual signs or symptoms
Not Recovered/Not 
Resolved (Continuing)Either incomplete improvement or no improvement of an AE, such that it remains 
ongoing
Fatal Outcome of an AE is death. â€œFatalâ€ will be used when death is a t least possibly 
related to the AE.
Unknown Outcome of an AE is not known (e.g., a subject lost to follow-u p)
AE: adverse event.
[IP_ADDRESS] Treatment Given
The investigator ensures adequa te medical care is provided to s ubjects for any AEs, including 
clinically significant laborato ry values related to study drug.  In addition, the investigator will 
describe whether any treatment w as given for the AE. â€œYesâ€ is u sed if any treatment was 
given in response to an AE and may i nclude treatments such as o ther medications, 
hospi[INVESTIGATOR_059], surgery, or physic al therapy. â€œNoâ€ indicates t he absence of any kind of 
treatment for an AE.
Protocol VX14-661-109, Version 4.0 Page 70 of 81
Vertex Pharmaceuticals Incorporated13.1.2 Serious Adverse Events
[IP_ADDRESS] Definition of a Serious Adverse Event
An SAE is any AE that meets any of the following outcomes:
xFatal (death, regardless of cause, that occurs during participa tion in the study or occurs 
after participation in the stu dy and is suspected of being a de layed toxicity due to 
administration of the study drug) 
xLife-threatening, such that the subject was at immediate risk o f death from the reaction as 
it occurred 
xInpatient hospi[INVESTIGATOR_419711]/incapacity (disability is defined as a substantial 
disruption of a person's abilit y to conduct normal life functio ns) 
xCongenital anomaly or birth defect 
xImportant medical event that , based upon appropriate medical ju dgment, may jeopardize 
the subject or may require medi cal or surgical intervention to prevent 1 of the outcomes 
listed above (e.g., an a llergic bronchospasm requiring intensiv e treatment in an 
emergency room or at home) 
If a subject has a hospi[INVESTIGATOR_29918] (e.g. surgery) for an event or condition that 
occurred before the subject si gned the ICF, and the hospi[INVESTIGATOR_419712], the hospi[INVESTIGATOR_419713], unless an A E caused the hospi[INVESTIGATOR_419714] d relative to what was planned. In addi tion, hospi[INVESTIGATOR_419715] (e.g ., social hospi[INVESTIGATOR_419716]) should not 
be considered to indicate an SAE. 
Clarification will be m ade between the terms  â€œseriousâ€ and â€œsev ere,â€ because they are not 
synonymous. The term â€œsevereâ€ is often used to describe the int ensity (severity) of a specific 
event, as in mild, moderate, or s evere myocardial infarction. T he event itself, however, may 
be of relatively minor medical s ignificance, such as a severe h eadache. This is not the same 
as â€œserious,â€ which is based on s ubject/event outcome or action  described above, and is 
usually associated with events that pose a threat to a subject' s life or functioning. 
Seriousness, not severity, serves as a guide for defining exped ited regulatory reporting 
obligations.  
[IP_ADDRESS] Documentation of Serious Adverse Events
All SAEs that occur after obtai ning informed c onsent and assent  (where applicable) through 
the Safety Follow-up Visit, reg ardless of causality, will be re ported by [CONTACT_139409]. In addition, all SAEs t hat occur after the Safety F ollow-up Visit and are 
considered related to study drug (s) will be reported to Vertex GPS within 24 hours .
SAEs will be recorded on the Verte x Organized Safety Informatio n Collection Form 
(hereafter referred to as the â€œSAE  Formâ€) using a recognized me dical term or diagnosis that 
accurately reflects the event. S AEs will be assessed by [CONTACT_419754]14-661-109, Version 4.[ADDRESS_529367] (if applicable), befo re study participation. The me thod of obtaining and 
documenting the informed consent and assent (if applicable) and  the contents of the consent 
will comply with ICH GCP and all a pplicable laws and regulation s and will be subject to 
approval by [CONTACT_139411]. 
13.2.[ADDRESS_529368] the safety of the  subjects, the scope of the 
investigation, or the scientific  quality of the study (i.e., ef ficacy assessments) will require 
IRB/IEC notification before imple mentation, except where the mo dification is necessary to 
eliminate an apparent immediate  hazard to human subjects. Verte x will submit all protocol 
modifications to the required regulatory authorities.
When circumstances require an immediate departure from procedur es set forth in the 
protocol, the investigator will c ontact Vertex to discuss the p lanned course of action. If 
possible, contact [CONTACT_419755]. Any departures 
from protocol will be fully doc umented in the source documentat ion and in a protocol 
deviation log. 
13.2.4 Access to Records
The investigator will make the o ffice and/or hospi[INVESTIGATOR_1097] o f subjects enrolled in this study 
available for inspection by [CONTACT_419756]. The records will also be available for direct i nspection, verification, and 
copying, as required by [CONTACT_774], by [CONTACT_419757] (FDA and others). The  investigator will comply with  applicable privacy and 
security laws for use and disc losure of informa tion related to the research set forth in this 
protocol. 
13.2.[ADDRESS_529369] confidentialit y, all electronic case report  forms (eCRFs), study reports, 
and communications relating to t he study will identify subjects  by [CONTACT_776]. 
As required by [CONTACT_17926], the investigator will allow  Vertex and/or its 
representatives access to all pertinent medical records to allo w for the verification of data 
gathered in the eCRFs/SAE Forms and the review of the data coll ection process. The FDA 
(or other regulatory authority) may also request access to all study records, including source 
documentation, for inspection. 
As applicable, in accordance wit h the Health Insurance Portabil ity and Accountability Act 
and associated privacy regulati ons, a subject authorization to use personally identifiable 
health information may be requi red from each subject before res earch activities begin. This 
authorization document will clear ly specify which parties will have access to a subject's
personal health infor mation, for what purpos e, and for how long . 
13.2.[ADDRESS_529370] Retention
The investigator will maintain all study records according to IC H GCP guidelines and/or 
applicable local regulatory requi rement(s), whichever is longes t, as described in the Clinical 
Trial Agreement. If the investigator withdraws from the respons ibility of keepi[INVESTIGATOR_419717]14-661-109, Version 4.0 Page 73 of 81
Vertex Pharmaceuticals Incorporatedrecords, custody will be trans ferred to a person willing to acc ept the responsibility and 
Vertex will be notified.
13.2.7 Study Termination
At any time, Vertex may terminate this study in its entirety or  may terminate this study at any 
particular site. In a ddition, for reasonable cause, either the investigators or their IRBs/IECs 
may terminate the study at their center.
Conditions that may lead to reas onable cause and warrant termin ation include, but are not 
limited to:
xSubject or investigator noncompliance 
xUnsatisfactory subject enrollment
xLack of adherence to protocol procedures 
xLack of evaluable a nd/or complete data
xPotentially unacceptable risk to study subjects
xDecision to modify drug  development plan 
xDecision by [CONTACT_155434].
13.[ADDRESS_529371] will be enter ed into an eCRF by [CONTACT_320216] a secure, validat ed web-based electronic data c apture (EDC) application. 
Vertex will have read-only acce ss to site-entered clinical data  in the EDC application.  
Instances of missing, discrepant , or uninterpretable data will be queried with the investigator 
for resolution. Any changes to s tudy data will be made to the e CRF and documented in an 
audit trail, which w ill be maintained withi n the clinical datab ase.
13.4 Monitoring
Monitoring and auditing procedur es developed or approved by [CONTACT_419758]. On-s ite checking of the eCRFs/SAE F orms for completeness 
and clarity, cross-checking wit h source documents, and clarific ation of administr ative matters 
will be performed. 
The study will be monitored by [CONTACT_139411]. Monitori ng will be done by [CONTACT_49915] a representative of  Vertex, or designee (study site  monitor), who will review the 
Protocol VX14-661-109, Version 4.0 Page 74 of 81
Vertex Pharmaceuticals IncorporatedeCRFs/SAE Forms and source docum ents. The study site monitor wi ll ensure that the 
investigation is conducted accordin g to the protocol design and  regulatory requirements. 
13.[ADDRESS_529372]. It is the investigator's responsibility 
to ensure the accuracy, completeness, clarity, and timeliness o f the data reported in the 
subject's eCRFs. Source documen tation supporting the eCRF data will indicate the subject's 
participation in the study and w ill document the dates and deta ils of study procedures, AEs, 
other observations, and subject status.  
The investigator, or designated r epresentative, will complete t he eCRFs as soon as possible 
after information is collected. 
The audit trail entry will show  the user's identification infor mation and the da te and time of 
any correction. The investigator m ust provide for mal approval o f all the information in the 
eCRFs, including any changes ma de to the eCRFs , to endorse the final submitted da ta for the 
subjects for whom the inves tigator is responsible.  
Vertex will retain the eCRF da ta and corresponding audit trails . A copy of the final archival 
eCRFs in the form of a compact  disc or other electronic media w ill be placed in the 
investigator's study file.
Protocol VX14-661-109, Version 4.0 Page 75 of 81
Vertex Pharmaceuticals Incorporated
Protocol VX14-661-109, Version 4.0 Page 76 of 81
Vertex Pharmaceuticals Incorporated14 REFERENCES
1 Cystic Fibrosis Foundation Webs ite [Internet]. Available at: 
http://www.cff.org/AboutCF/. Accessed 11 November 2014. 
2 Kriendler JL. Cystic fibrosis: exploiting its genetic basis in the hunt for new 
therapi[INVESTIGATOR_014]. Pharmacol Ther. 2010;125:219-29. 
3FDA Office of Orphan Products Dev elopment (OOPD) [Internet]. Av ailable at: 
http://www.fda.gov/ForIndustry/Developi[INVESTIGATOR_419718]/defa
ult.htm. Accessed 11 November 2014. 
4  The Committee for Orphan Medicin al Products (COMP) [Internet] . Available at: 
http://www.ema.europa.eu/ema/inde x.jsp?curl=pages/about_us/gene ral/general_conte
nt_000263.jsp&murl=menus/about_us/about_us.jsp&mid=WC0b01ac0580 028e30.
Accessed 11 November 2014. 
5 Cystic Fibrosis Foundation. Cystic  Fibrosis Foundation Patient  Registry 2009 annual 
data report. Bethesda, Maryland; 2011.
6Flume PA, Van Devanter DR. State  of progress in treating cystic  fibrosis respi[INVESTIGATOR_23697]. BMC Med. 2012;10(1):88. 
7Cystic Fibrosis Mutation Database (CFTR1). Cystic Fibrosis Cent re at the Hospi[INVESTIGATOR_419719] [Internet]. Available at: 
http://www.genet.sickkids.on.ca/ cftr/StatisticsPage.html. Acces sed 
11 November 2014.
8 Castellani C, Bonizzato A, Cabri ni G, Mastella G. Newborn scre ening strategy for 
cystic fibrosis: a field study  in an area with high allelic het erogeneity. Acta Paediatr. 
1997;86(5):497-502. 
9 Van Goor F, Hadida S, Grootenhui s P. Pharmacological rescue of  mutant CFTR
function for the trea tment of cystic fibrosis. Top Med Chem. 20 08;3:91-120. 
[ADDRESS_529373] of genoty pe on phenotype 
and mortality in cystic fibrosis:  a retrospective cohort study.  Lancet. 
2003;361(9370):1671-6. 
11  Cystic Fibrosis Foundation. Cys tic Fibrosis Foundation Patien t Registry 2011 annual 
data report. Bethesda, Maryland; 2012. 
12  European Cystic Fibrosis Society. European Cystic Fibrosis So ciety Patient Registry 
2008-2009. Karup, Denmark; 2012. Available at: http://www.ecfs.eu/files/webfm/web files/File/ecfs_registry/ECFS PR_Report0809_v3
2012.pdf. Accessed [ADDRESS_529374] cystic fibrosis. Cell. 1990;63:827-34. 
14 Dalemans W, Barbry P, Champi[INVESTIGATOR_139362] G, Jallat S, Dott K, Dreyer D,  et al. Altered 
chloride ion channel kinetics a ssociated with the delta F508 cy stic fibrosis mutation. 
Nature. 1991;354:526-8. 
15 Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med.  
2005;352:1992-2001. 
16 Vertex Pharmaceuticals Incorpor ated. Report G016. Effects of V RT-893661 on 
CFTR-mediated chloride secre tion in human bronchial epi[INVESTIGATOR_24603] i solated from cystic 
fibrosis subjects. Repor t date: 17 February 2010. 
17 Lukacs GL, Chang XB, Bear C, K artner N, Mohamed A, Riordan JR,  et al. The delta 
F508 mutation decreases the stability of cystic fibrosis transm embrane conductance 
regulator in the plasma membran e. Determination of functional h alf-lives on 
transfected cells. J Biol Chem. 1993;268:[ZIP_CODE]-8. 
18Vertex Pharmaceuticals Incorporated. VX-661 Investigator's Broc hure, Version 7.0. 
Report date: 08 May 2015.  
19Vertex Pharmaceuticals Incorporated. Ivacaftor (VX-770) Investi gator's Brochure, 
Version 12.0. Report date: 08 May 2015. 
20Miller MR, Hankinson J, Brusasco V , Burgos F, Casaburi R, Coate s A, et al. 
Standardisation of spi[INVESTIGATOR_23943] y. Eur Respir J. 2005;26:319-38. 
21  Edginton AN, Schmitt W, Voith B, Willmann S. A mechanistic ap proach for the 
scaling of clearance in child ren. Clin Pharmacokinet. 2006;45(7 ):683-704. 
22 Wilcschanski M, Zielenski J, Mar kiewicz D, Tsui LC, Corey M, L evison H, et al. 
Correlation of sweat chloride c oncentration with classes of the  cystic fibrosis 
transmembrane conductance regula tor gene mutations. J Pediatr. 1995;127:705-10. 
23 Rowe S, Accurso F, Clancy JP. D etection of cystic fibrosis tra nsmembrane 
conductance regulator activity in early-phase clinical trials. Proc Am Thorac Soc. 
2007;4:387-98. 
24 Quittner AL, Modi A, Cruz I. Systematic review of health-relat ed quality of life 
measure for children with respi [INVESTIGATOR_14437]. Pediatr Respi r Rev. 2008;9:220-32. 
25 Goss C, Quittner AL. Patient -reported outcomes in cystic fibro sis. Proc Am Thorac 
Soc. 2007;4:1-9. 
26 Modi AC, Quittner AL. Validati on of a disease-sp ecific measure  of health-related 
quality of life for children with c ystic fibrosis. J Pediatr Ps ychol. 2003;28(8):535-45. 
27 Wenninger K, Aussage P, Wahn U , Staab D. German Cystic Fibrosi s Questionnaire 
study group. The revised German Cystic Fibrosis Questionnaire: validation of a 
Protocol VX14-661-109, Version 4.0 Page 78 of 81
Vertex Pharmaceuticals Incorporateddisease-specific health-relate qua lity of life instrument. Qual  Life Res. 
2003;12(1):77-85. 
28 Henry B, Aussage P, Grosskopf C , Goehrs JM. Development of the  Cystic Fibrosis 
Questionnaire (CFQ) for assessing  quality of life in pediatric and adult patients. Qual 
Life Res. 2003;12(1):63-76. 
29 Hankinson JL, Odencrantz JR, Fed an KB. Spi[INVESTIGATOR_419720] v alues from a 
sample of the general US populati on. Am J Respir Crit Care Med.  1999;159:179-87. 
30 Wang X, Dockery DQ, Wypij D, Fay ME, Ferris BG. Pulmonary func tion between 6 
and 18 years of age. Pediatr Pulmonol. 1993;15:75-88. 
31 Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a  consensus statement. 
Cystic Fibrosis Foundation Cons ensus Panel. J Pediatr. 1998;132 (4):589-95. 
32 Levey AS, Bosch JP, Breyer Lewis J, Greene T, Rogers N, Roth D . A more accurate 
method to estimate glome rular filtration rate from serum creati nine: a new prediction 
equation. Ann Intern Med. 1999;130:461-70. 
33 Levey AS, Coresh J, Greene T, S tevens LA, Zhang Y, Hendriksen S, et al. Using 
standardized serum creatinine  values in the modification of die t in renal disease study 
equation for es timating glomerular filtra tion rate. Ann Intern Med. 2006;145:247-54. 
[ADDRESS_529375] asma creatinine concentration  in children. Arch Dis 
Child. 1976;51(11):875-8. 
35 Quitttner Al, Buu A, Messer MA, M odi AC, Watrous  M. Developmen t and validation 
of the cystic fibrosis questionna ire in the Un ited States: a he alth-related quality of life 
measure for cystic fibrosis. Chest. 2005;128:2347-54. 
[ADDRESS_529376] of aerosolized recombina nt human DNase on exacerbations of respi[INVESTIGATOR_419721] i n patients with cystic fibr osis. N Engl J Med. 
1994;331:637-42. 
375DPVH\%:'DYLHV-0F(OYDQH\1*7XOOLV(%HOO6&'ÄœHYtQHN 3HWDO$&)75
potentiator in patients wit h cystic fibrosis and the G551D  mutation. N Engl J Med. 
2011;365:1663-72. 
Protocol VX14-661-109, Version 4.0 Page 80 of 81
Vertex Pharmaceuticals Incorporated15.2 Investigator Signature [CONTACT_209226] #: VX14-661-109 Versi on #: 4.0 Version Date 18 April 2017
Study Title: A Phase 3, Randomiz ed, Double-Blind, Ivacaftor-Con trolled, Pa rallel-Group 
Study to Evaluate the Efficacy and Safety of VX-[ADDRESS_529377] the study according to 
its terms. I understand that all information concerning VX-661 and ivacaftor and this 
protocol supplied to me by [CONTACT_139369] (Vertex) is confidential.  
Printed Name
[CONTACT_419759]14-661-109, Version 4.0 Page 81 of 81
Vertex Pharmaceuticals Incorporated16 APPENDIX A: SECOND CFTR ALLELE MUTATIONS INCLUDED 
FOR SUBJECTS WHO ARE HETEROZYGOUS FOR THE
F508del-CFTR MUTATION
Per the study eligibilit y criteria, heterozygous F508del-CFTR  subjects must have a second 
CFTR allele that encodes a mutation with a gating defect clinically demonstrated to be 
ivacaftor-responsive. The list be low represents acceptable muta tions. 
CFTR Mutations With a Gatin g Defect Clinically Demonstrated to be Iv acaftor-
Responsive
R117H
G178R
S549N
S549R
G551D
G551S
G1244E
S1251N
S1255P
G1349D
Source: CFTR2.org [Internet]. Baltimore (MD): Clinical and func tional translation of CFTR. The Clinical and 
Functional Translation of CFTR (C FTR2), US Cystic Fibrosis Foun dation, Johns Hopkins University, the 
Hospi[INVESTIGATOR_31331]. Available at: http://www.cftr2.org/ . Accessed 15 September 2014